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1.1 .  EN GL ISH  
Telomeres are nucleoprotein structures that protect the chromosomal ends from being 
recognized by DNA repair mechanisms as DNA double strand breaks. The Telomeric DNA is 
bound by various proteins that force the whole structure to fold in the so-called telomeric 
loop, hiding the DNA ends in the double stranded DNA. One of those sheltering proteins is 
the telomere repeat binding factor 1 (TRF1) which binds to the double-stranded telomeric 
DNA and is implicated in telomere length regulation. TRF1-deficient mice are embryonic 
lethal at the blastocyst stage and the conditional deletion of TRF1 in stratified epithelia leads 
to hair follicle stem cell defects, suggesting thus a role for TRF1 in stemness.  
To address this and also the possibility of using TRF1 as an in vivo telomere length 
marker, here we generated a reporter mouse carrying a knock-in (KI) allele in which TRF1 is 
fused to the reporter protein eGFP. We find that eGFP-TRF1 expression is maximal at the 
adult stem cell compartments in the mouse, including the hair follicle stem cell niche and 
Lgr5-positive (Lgr5+) and Lgr5-low/negative stem cells at the intestinal crypts, and that eGFP-
TRF1 expression is uncoupled from telomere length. Conditional deletion of TRF1 in the 
small intestine leads to a rapid collapse of the villi/crypt structures coincidental with increased 
DNA damage and apoptosis, indicating that TRF1 is essential to maintain small intestine 
homeostasis. Thus, TRF1 both marks adult stem cell compartments and is essential for their 
functionality. In line with this, we found very high levels of eGFP-TRF1 in induced pluripotent 
stem (iPS) cells, levels that are uncoupled from telomere elongation associated to 
reprogramming. TRF1 in iPS cells is expressed heterogeneous and coincident with the in-
built heterogeneity of Nanog expression in iPS cell colonies. Selection of high eGFP-TRF1 
iPS cells correlated with a higher pluripotency as indicated by their ability to form teratomas 
and chimeras. By using various loss-of-function approaches, we show that TRF1 is 
necessary for both the induction and the maintenance of pluripotency, by preventing the 
induction of DNA damage response and apoptosis. Finally, supporting the notion that TRF1 
is a key factor for pluripotency we make the unprecedented finding that TRF1 is a direct 
target of the transcription factor Oct3/4, which binds to the TRF1 promoter and increases the 
transcription of TRF1, thus providing a mechanistic link between TRF1 and pluripotency.  
These findings render TRF1 a novel marker for stem cells, those cells having the highest 
abundance of TRF1 in a given tissue. Also they deploy the eGFP-TRF1 mouse model as a 
useful tool for following up such stem cells in vivo and in vitro. 
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1.2 .  DEU TSC H  
Werden lose Chromosomenenden von DNS-Reparaturmechanismen erkannt führt dies 
zu Chromosomenfusionen, Zellseneszenz und Apoptose. Telomere, die Endstücke 
chromosomaler DNS sind Nukleoprotein-Strukturen mit der Aufgabe die 
Chromosomenenden davor zu schützen. Die telomerische DNS wird dabei von 
verschiedenen Proteinen erkannt, gebunden und zu einer Schleife geformt, deren Ende in 
der telomer-duplex DNA versteckt wird. Eines dieser Schutzproteine ist der „Telomere repeat 
binding factor 1“ (TRF1), welches die doppelsträngige Telomer-DNS bindet und bei der 
Regulation der Telomerlänge beteiligt ist. Wird TRF1 depletiert, sterben Embryonen bereits 
als Blastozysten, zeigen aber keine Telomeranomalitäten. Das konditionelle Ausschalten von 
TRF1 im mehrschichtigen Epithel (Keratin 5 exprimierendes Epithel) führt jedoch zu hoher 
Telomerfragilität und zum Verlust von Haarfollikeln was auf einen Stammzelldefekt hindeutet.  
Um mögliche Stammzelleigenschaften sowie die Möglichkeit von TRF1 als in vivo 
Telomerlängenindikator zu eruieren, wurde hier eine knock-in Maus generiert, bei der eine 
eGFP-Kassette in das Aminoende des TRF1-Lokus fusioniert wurde. Mit diesem Model 
konnte ich zeigen, dass die eGFP-TRF1-Expression in den adulten Stammzellnischen der 
Haarfollikel und der Dünndarm-Krypten erhöht ist. Konditionelles ausknocken von TRF1 im 
Dünndarm führte zu einem schnellen Kollaps der Villi/Krypt-Struktur sobald TRF1 in allen 
Stammzellen eliminiert war. Übereinstimmend mit den erhöhten TRF1-Levels in adulten 
Stammzellen, zeigten auch induzierte, pluripotente Stammzellen (iPSz) eine deutlich erhöhte 
Expression von eGFP-TRF1, was aufgrund aktiver Telomerase und sich verlängernder 
Telomere erwartet werden konnte. Überraschenderweise ist die Menge an TRF1 während 
des Reprogramierungsprozesses überproportional zur Telomerlänge angestiegen; auch in 
Zellen die keine Fähigkeit hatten die Telomere zu verlängern. Die Expression von eGFP-
TRF1 in iPS-Zellkolonien ist heterogen und korreliert mit Nanog, einem Stammzellmarker der 
in iPS-Zellen ebenfalls variiert und die Pluripotenz der Zellen positiv beeinflusst. IPS-Zellen 
mit hoher eGFP-TRF1 Expression waren potenter, subkutane Teratome zu bilden und 
beteiligten sich an der Formation von Chimären. Mit verschiedenen TRF1 knock-out und 
knock-down Studien konnte ich belegen, dass TRF1 für die Induktion, wie auch für die 
Aufrechterhaltung der Pluripotenz essentiell ist. Ebenfalls bewiesen wir, dass OCT3/4,  ein 
Transkriptionsfaktor für Pluripotenzgene, an die TRF1 Promoter-Region bindet und die TRF1 
Transkription positiv beeinflusst.   
  Diese Resultate zeigen TRF1 als einen wesentlichen Faktor der für Pluripotenz und 
einem neuen Marker für Stammzellen in vitro und in vivo. EGFP-TRF1 konnte aber nicht als 
in vivo Telomerlängenindikator etabliert werden. 
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1.3 .  ESP AÑ OL  
Los telómeros son estructuras nucleoproteicas que evitan que los extremos de los 
cromosomas sean reconocidos por los mecanismos de reparación del ADN como roturas en 
la doble hebra de ADN. El ADN telomérico está unido a varias proteínas que facilitan la 
formación del denominado bucle telomérico, y que protege los extremos del ADN 
bicatenario. La proteína TRF1 (telomere repeat binding factor 1) es un miembro del complejo 
proteíco  especializado de protección telomérica  que se une al ADN  cadena doble y está 
implicada en la regulación de la longitud telomérica. Los ratones deficientes en TRF1 
adolecen de letalidad embrionaria en la etapa de blastocito y la deleción condicional de esta 
proteína en el epitelio estratificado conduce a defectos en las células madre del folículo 
piloso, lo que sugiere por tanto una implicación funcional de TRF1 en pluripotencia.  
Con el fin de elucidar esta conexión entre TRF1 y pluripotencia y también el posible 
empleo de  TRF1 como un marcador de longitud telomérica in vivo, generamos un ratón 
“reporter” que contiene un alelo knock-in (KI) en el que TRF1 está fusionada a la proteína 
eGFP. La expresión de eGFP-TRF1 alcanza, de manera independiente de la longitud 
telomérica, valores máximos en los compartimentos de células madre adultas, entre los que 
se incluyen el nicho de células madre del folículo piloso y las células madre Lgr5-positivas 
(Lgr5+) y Lgr5-negativas (Lgr5-) de las criptas intestinales. La deleción condicional de TRF1 
en el intestino delgado desencadena un rápido colapso de las vellosidades y criptas 
intestinales, coincidente con un aumento en el daño en el ADN y en la apoptosis, lo cual 
indica que TRF1 es esencial en el mantenimiento de la homeostasis del intestino delgado. 
Por consiguiente, TRF1 demarca los compartimentos de células madre adultas y es 
indispensable para su funcionalidad. En consonancia con lo anterior, describimos la 
presencia de niveles muy elevados de eGFP-TRF1 en las células madre pluripotentes 
inducidas (células iPS), valores que son independientes del alargamiento telomérico 
asociado a la reprogramación nuclear. Además, los niveles de TRF1 entre las diferentes 
células de las colonias de Ips son heterogéneos y coincidentes con la también 
intrínsecamente heterogénea expresión de Nanog. En las células iPS los altos niveles de 
eGFP-TRF1 correlacionan con una mayor pluripotencia, asociada a una mayor capacidad 
para formar teratomas y quimeras. Por medio de diferentes ensayos de pérdida de función, 
demostramos que TRF1 es necesaria para la inducción y mantenimiento de la pluripotencia, 
evitando que se desencadene la respuesta de daño en el ADN y la apoptosis. Por último, la 
idea de que TRF1 sea un factor clave se ve respaldada por el hallazgo sin precedentes de 
que TRF1 es una diana directa del factor de transcripción Oct3/4, cuya unión al promotor de 
TRF1 activa la transcripción de TRF1, lo que proporciona un mecanismo que conecta la 
proteína telomérica TRF1 con la pluripotencia.  
Estos resultados convierten a TRF1 en un nuevo marcador de células madre, debido a que 
su expresión es máxima en las células madre de un tejido dado y  al modelo de ratón eGFP-
TRF1 en una útil herramienta para el seguimiento de estas células madre in vivo e in vitro. 
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3.1 .  TH E  H ISTOR Y OF  TELOM ER ES  
Telomeres where first mentioned by Hermann Müller and Barbara McClintock. They 
noticed that chromatic fusions were not present at the very end of chromosomes. Therefore, 
they postulated a protecting structure that defends the chromosomal extremities from fusion 
events (McClintock, 1941; Müller, 1938). This structure, as vague as its existence remained, 
was denominated telomere, a term deriving from the Greek words telos (end) and meros 
(part).  
In 1971 after the deoxyribonucleic acid (DNA) structure was revealed by Watson and 
Crick (Watson & Crick, 1953),  Alexey Olovnikov (Olovnikov, 1971) and later James Watson 
(Watson, 1972) postulated on theoretical grounds the “end replication problem” of the semi 
conservative DNA replication. They predicted that DNA, if its replication is RNA primed, could 
not be completely duplicated and that this must gradually shorten the DNA from its ends with 
every replication cycle. Olovnikov further suggested that this could be the underlying effect 
for the findings in the work of Hayflick and Moorhead (Olovnikov, 1971) that showed that 
human fibroblasts have a limit of 50 to 70 cell cycles before they abrogate replication and 
enter senescence. This limit is referred to as the Hayflick limit (Hayflick & Moorhead, 1961; 
Ohki et al, 2001; Olovnikov, 1971). It was Elisabeth Blackburn and Joe Gall that unravelled 
the structure of the chromosome ends and showed that eukaryotic telomeres consist of 
tandem repeated oligonucleotid sequences (Blackburn & Gall, 1978). As the telomeres 
shorten during lifetime, the discovery of the telomerase - a reverse transcriptase that can re-
elongate telomeres, was a next important milestone in telomere biology. This finding gave 
the basis for tools to demonstrate the dependency on telomere sustaining mechanisms of 
tumors and the tumor suppressive function of shortened telomeres (Blasco et al, 1997; 
Greider & Blackburn, 1985; Hanahan & Weinberg, 2000). 
35 years after the discovery of the first telomeric sequence, we now have a broad 
knowledge of telomeres and telomere-linked fields. Telomeres are now known to be 
nucleoprotein structures protecting the ends of chromosomes from being detected as double 
strand breaks by DNA repair mechanisms preventing fusions, recombination and 
degradation (Chan & Blackburn, 2002; de Lange, 2005). In vertebrates, telomeres are 
composed of the tandem repeated TTAGGG sequence that are bound by telomere specific 
proteins which force this nucleoprotein complex into a characteristic telomere structure (de 
Lange, 2005).  
 
Figure 1: Telomere structure 
Top: Visible is a condensed mouse 
metaphase chromosome. Its 
telomeres are labelled in red with a 
Cy3 fused PNA probe. It is observable 
that different arms of the same 
chromosome have a different telomere 
length. 
Middle and bottom: Schematic 
depiction of a vertebrate Telomere 
with the characteristic TTAGGG 
repeats and the single stranded 3’-G-
rich overhang. Within the different 
species the repeat number can 
change severely. 
3.2 .  STR U C TU R E OF  TEL OM ER E S   
Telomeric DNA in vertebrates are gene-poor regions at the ends of the linear 
chromosomes. They are constituted of tandem repeated 5’-TTAGGG-3’ sequences. In a 
healthy human these repeats span in average 5 to 15kB (de Lange et al, 1990) whereas the 
average murine telomere spans between 15 and 40kB depending on the genetic background 
(Hemann & Greider, 2000; Zijlmans et al, 1997). Within different organisms of the same 
species, telomere length is not homogeneous, varies from tissues to cell types, cells (Canela 
et al, 2007a; Flores et al, 2008) and even within different DNA ends of the same 
chromosome (Lansdorp et al, 1996; Zijlmans et al, 1997). These variations do not alter the 
function of the telomeres as long as their size does not underrun a critical length, required for 
a proper maintenance of genomic stability (Blasco et al, 1997; Lee et al, 1998). At the end of 
the repetitive telomere sequence, there is a guanine-rich, single stranded 3’ overhang of 
approximately 150 to 200 bp (also known as G-strand overhang; Fig 1). The presence of this 
structure is a direct consequence of the end replication problem that occurs in RNA primed 
DNA duplication (further explanation in point 3.5) (de Lange, 2002; Klobutcher et al, 1981; 
Ohki et al, 2001; Wright et al, 1997).   
 
 
 
3.3 .  TH E  SH ELTER IN  C OM PLEX PR OTEIN S  
For scaffold and protection purposes a six-protein complex known as the shelterin is 
bound to mammalian telomeres (de Lange, 2002; de Lange, 2005). Out of these proteins, 
two are bound to the repeats of double stranded telomeric DNA and one binds the single 
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DNA strand of the G-rich overhang. The double strand binding proteins are the Telomere 
Repeat binding Factor 1 (TRF1) and the Telomere Repeat binding Factor 2 (TRF2), two 
proteins that show a high primary structure homology (Bianchi et al, 1997; Bilaud et al, 1997; 
Broccoli et al, 1997; Chong et al, 1995). TRF1 and TRF2 interact with each other through 
TRF1 Interacting Nuclear factor2 (TIN2) that itself also binds to TPP1 (Fig. 2) (Houghtaling et 
al, 2004; Ye et al, 2004a). Protection Of Telomeres (POT1) binds to the single stranded G-
rich overhang (de Lange, 2005) and it is connected to the shelterin complex through direct 
binding to TPP1, the mouse homolog of ACD (Fig. 2A) (Houghtaling et al, 2004; Ye et al, 
2004b). RAP1 binds TRF2 and is implicated in Telomere length alteration but it is not 
required for correct telomere capping. In addition, it has several extratelomeric roles such as 
a transcriptional modulator of NF-κB or the silencing of subtelomeric proteins (Martinez & 
Blasco, 2011; Martinez et al, 2010). Table 1 summarizes the telomeric roles of the shelterin 
proteins. 
In mammals, complementary proteins bind to the telomere repeat binding factors. TRF1 
for example is associated with Tankyrase1, Tankyrase2 and PINX1 (Chen et al, 2008) which 
will be discussed in more detail in chapter 3.9. TRF2 is associated with several proteins that 
have a role in DNA repair. Amongst them are the helicases WRN and BLM, the DNA-PKs 
complex (associated with non-homologous end joining (NHEJ)), the MRE11/NBS1/RAD50 
complex (associated with homologous recombination (HR)), the ADP-ribosilases PARP1 and 
PARP2 (associated with base excision repair (BER)), the complex of the endonucleases 
ERCC1/XPF (associated with the nucleotide excision repair (NER)) (Dantzer et al, 2004; 
Opresko et al, 2002; Zhu et al, 2000; Zhu et al, 2003) and Apollo/SNM1B nuclease 
implicated in the telomere end modulation (Wu et al, 2012). Even though the role of these 
proteins at the telomere is not exclusive, they are important for maintaining the protective 
function of telomeres. 
 
 
 
 
 
 
 
Proteins Role at the telomere 
TRF2, TRF1, TIN2, TPP1 and RAP1 Protection from recombination 
POT1 G-strand overhang protection 
TRF2, TRF1, TIN2, TPP1 and RAP1 Length regulation 
TRF1, TRF2, POT1, (RAP1) Inhibition of DNA damage response 
TRF1 Telomere replication facilitation 
TPP1 Telomerase recruitment 
Table 1: Roles of the different shelterin proteins at the telomeres as known up to date. 
Many of them also have extra-telomeric roles that are not indicated here. RAP1 null 
induces DDR but does not increase telomere fusions. Reviewed by (Martinez & Blasco, 
2011) 
  
 
 
 
 
 
 
 
 
 
 
3.4 .  TH E  T-L OOP  M OD EL  AN D  DNA  D AM AG E  RESPON SE  
According to a widely accepted hypothesis, mammalian telomeres can to have two 
known conformations. They can either be linear, or they can be closed, forming a structure 
known as the telomere loop (T-loop), as shown in Figure 2 B&C. The linear telomere 
conformation (Fig. 2A) has the advantage that the telomerase can access the telomere 
easily but this suffers from a major drawback: In this state, the chromosomal end remains 
unprotected in the nucleoplasma (de Lange, 2002; Loayza & De Lange, 2003; Ye & de 
Lange, 2004). This is the advantage and probably the evolutionary reason why a telomeric 
loop conformation was established. In the T-loop the telomeric DNA-Protein complex forms a 
characteristic structure where the single stranded G-rich overhang is invading the double 
stranded telomeric DNA. At the double strand DNA entry-site this invasion creates a 
displacement D-loop (in which the G-rich strand presents additional binding sites to POT1) 
(Fig. 2B) (Goytisolo & Blasco, 2002; Greider, 1999; Griffith et al, 1999). This protecting 
structure is important in eukaryotic cells as the DNA-damage repair (DDR) mechanisms can 
recognize and “repair” broken DNA strands. These mechanisms re-join two free ends of DNA 
regardless whether they result from a DNA break or from unprotected chromosome ends. 
Thus one of the main functions of telomeres is to hide the chromosome ends from being 
detected and processed as DNA double strand breaks (Chan & Blackburn, 2004). 
Figure 2: Shelterin and T-loop 
structure.  
A: Schematic depiction of the 
nucleoprotein structure of a telomere 
and the binding pattern and partners of 
the shelterin proteins. Of note is that 
only TRF1, TRF2 and POT1 are directly 
binding to telomeric DNA. RAP1, TIN2 
and TPP1 are localized at the telomere 
via a linker protein.  Visible on the right 
is the enzyme Telomerase composed by 
the subunits TERT and TERC.   
B: Telomere nucleoprotein structure 
forming the T-loop by the invasion of the 
G-strand overhang into the telomeric 
DNA, leaving a displacement D-loop that 
is bound by POT1. Adapted from 
(Martinez & Blasco, 2011).   
C: Transmission electron-microscope 
picture of telomeric chromatin forming up 
the T-loop in HELA cells (Griffith et al, 
1999). 
A 
B 
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Figure 3: DNA damage response of by dysfunctional 
telomeres.  
Dysfunctional telomeres that can be induced either by 
critically short telomere of insufficient telomere capping 
by other reasons, force the cell into senescence and 
apoptosis in a p53/pRB mediated manner. Dysfunctional 
telomeres are made visible with a double labelling of 
telomeres and a DNA damage marker like 53BP1. 
Depiction is adapted from (de Lange, 2005). 
 
 
Nevertheless, telomeres may remain 
in the open conformation either due to 
telomere shortening to a critical length 
that is not sufficient to initiate a T-loop, 
or by the lack of telomeric proteins 
destabilizing this sheltering complex. 
At sites of free chromosome ends, it is 
proposed that proteins responsible for 
the DDR transduction (53BP1, γH2AX, 
NBS1, ATM, ATR, DNA-PK) 
accumulate and induce a signalling 
cascade that results in transcriptional 
activation of tumor suppressor genes 
such as p53, p21, p16, Chk1 and 
Chk2. They force cells with DDR 
signalling into p53/pRB-dependent 
senescence or apoptosis (Fig.3) 
(Artandi & Attardi, 2005; Goytisolo & 
Blasco, 2002; Martinez et al, 2009; 
Sfeir et al, 2009; Smogorzewska & de 
Lange, 2002; van Steensel & de Lange, 1997).  Telomeres that are recognized by DDR 
mechanisms and show corresponding marks are referred to as telomere dysfunction induced 
foci (TIF). The activated DNA-PK leads to the initiation of NHEJ, resulting in cells that show 
end-to-end telomere fusions from both, different chromosomes and sister chromatids. This 
evades the immediate initiation of senescence and is another marker for telomere 
dysfunction (Donate & Blasco, 2011; Martinez et al, 2009; Sfeir et al, 2009). 
 
3.5 .  TELOM ER E SH OR TEN IN G  
As mentioned earlier, the 5’ end of telomeres cannot be duplicated completely what 
causes a shortening of 50 to 200bp in every cell cycle. The reason for this decrease lies in 
the antiparallel characteristics of the double DNA and the nature of semiconservative DNA 
replication.  
DNA-polymerases can only add bases to the 3’ end of a newly synthesised DNA strand. 
Therefore, in replication forks, the daughter DNA strands are distinguished in a leading and a 
lagging strand (Fig.4). In the leading strand the DNA polymerase can continuously operate 
Figure 4: The end replication 
problem 
Top: Depicted is a replication fork 
progressing towards the telomere. 
The DNA replication of the lagging 
strand cannot be completed as the 
DNA polymerase needs a 3’ end 
that is not available at the distal end 
of the telomere. As a result, the 
DNA shortens with every cell cycle.  
Bottom: Post replication nucleases 
(Apollo and Exo1) degrade parts of 
the 5’ telomere end of the leading 
strand. This allows the blunt ended 
DNA to form a G-strand overhang 
and the initiation of a protecting T-
loop, leaving a shortened telomere. 
 
 
along with the progression of the replication fork machinery in a 5’-3’ direction. On the 
lagging strand however, the polymerase moves in the opposite direction to the replication 
fork and DNA synthesis must be accomplished in a discontinuous manner. Therefore, in the 
opened DNA of the replication fork, DNA-primases introduce short pieces of complementary 
RNA to the lagging strand. They function as primers and give a 3’-OH substrate to the DNA-
polymerase for the synthesis of the lagging strand. Discontinuous DNA fragments, the 
Okazaki fragments, appear interspersed by RNA primers (Fig. 4) (Okazaki et al, 1967). In 
turn, these RNA-primers are further degraded and a DNA-polymerase fills the gap with 
corresponding DNA-bases. At the end of the chromosome, when the most distal RNA 
priming sequence is degraded the polymerase is not able to replicate the full DNA in this 
lagging manner due to its necessity of a 3’-hydroxy end. For this reason the newly 
synthesised 5’-DNA strand remains shorter than its complement, parental DNA strand.  This 
is the phenomenon of the end replication problem in semiconservative DNA replication and 
leads to a replication or age related telomere shortening (Ohki et al, 2001). On the other 
hand, the leading strand is synthesising the entire DNA, finishing blunt ended. Here the 
EXO1 and Apollo/SNM1B nucleases digest DNA from the 5’ end to form a G-strand 
overhang, required for the formation of the protective T-loop. This DNA degradation results in 
a shortened 5’ DNA strand and a further shortened telomere (Fig. 4) (Wu et al, 2012).  
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Another pathway for telomere shortening departs from the fact that telomeres are more 
prone to single strand damage due to oxidative stress when compared to the rest of the 
genome. This causes single strand breaks by Reactive oxygen species (ROS) that lead to an 
increased S1-nuclease sensitivity and concomitant telomere erosion (von Zglinicki et al, 
2000). Other reasons for telomere shortening are known. They are however of minor 
importance. 
3.6 .  TELOM E R ASE D EPEN D EN T T ELOM ERE  ELON G AT I ON  
To compensate for the loss in telomere length, cells can de-novo re-elongate telomeres 
with the enzymatic complex telomerase (Blackburn, 2001; Collins & Mitchell, 2002; Greider & 
Blackburn, 1985). This complex consists of a constitutive protein subunit, the telomerase 
reverse transcriptase (TERT) and an inducible telomere RNA subunit (TERC) (Fig. 2A). In 
addition, a single molecule of dyskerin1 (DKC1) is stabilizing the telomerase composite 
(Cohen et al, 2007). This complex forms up a reverse transcriptase that recognizes the 3’-
hydroxy group of the G-strand overhang where it acts as a reverse transcriptase, adding 
telomeric repeats. During this step, the RNA subunit TERC is used as a template which 
explains the repetitive TTAGGG sequence of telomeres (Greider & Blackburn, 1985). As 
mentioned earlier, the accessibility for the telomerase complex to the telomere depends on 
the telomere conformation. A short telomere or a telomere with low amounts of shelterins is 
more accessible for the telomerase due to its loose or open conformation. Consequently, in 
the closed form (T-loop) the 3’ end is less approachable impeding the access of the 
telomerase to the telomeres resulting in a more rapid shortening. This can be seen as a 
mechanism by which, the telomeres autoregulate their own length (Marcand et al, 1997). In 
the absence of the T-loop, it has been proposed that telomerase can protect short telomere 
by simply binding to them, hiding the DNA ends from DNA repair mechanisms (Masutomi et 
al, 2003). 
Telomerase is predominantly expressed in cells of the inner cell mass (ICM), embryonic 
stem (ES) cells and in several tissue specific adult stem cell compartments (Allsopp et al, 
2003; de Lange & DePinho, 1999; Greenberg et al, 1998; Hoffmeyer et al, 2012; 
Montgomery et al, 2011; Schepers et al, 2011; Varela et al, 2011). In adult stem cells 
however the telomerase activity is not sufficient to maintain telomere length over successive 
cell divisions and differentiation. The ensuing telomere shortening is suggested to be one of 
the molecular mechanisms underlying organism aging (Flores et al, 2008; Harley et al, 
1990). One possible exception is the testis, where TERT is expressed to high levels and 
elongates telomeres during lifespan so that older fathers have offspring with longer 
telomeres (Eisenberg et al, 2012; Montgomery et al, 2011).   
 3.7 .  AL T ER N ATIVE  M EC H AN ISM  OF  TELOM ER E LEN GTH  
M AIN T AI N IN G  
In the absence of a functional telomerase complex telomere length homeostasis can be 
achieved by a different mechanism. This alternative lengthening of telomeres (ALT) pathway 
is able to maintain or elongate the telomeric (and subtelomeric) DNA via homologous 
recombination. This pathway was found in various tumors and several immortalized cell 
lines. Cells that use the ALT pathway are characterized by the presence of highly 
heterogeneous telomere lengths and telomere association with promyelocytic leukaemia 
(PML) protein, forming the ALT-associated-PML bodies or APBs (Bryan et al, 1997; Bryan et 
al, 1995; Dunham et al, 2000; Muntoni & Reddel, 2005). This pathway however is not 
capable of maintaining the telomeres of protozoan organisms for a long period of time and is 
therefore of minor importance for counteracting the age related telomere loss.  
 
3.8 .  TELOM ER ES ,  SEN ESC EN C E AN D  AG I N G  
As seen above, telomeres get shorter with every DNA replication, until they have 
shortened to a critical length that does not allow the initiation of the T-loop conformation 
anymore. This leads to the appearance and the initiation of the DDR resulting in stalled 
proliferation (Vaziri, 1997). In vitro, human cells stop dividing after 50-70 cell cycles before 
they enter a state called replicative senescence which in vivo reduces the self renewing 
potential of corresponding tissues. It is thought that telomere shortening is one of the main 
causes of this limited duplication capacity (Harley et al, 1990). Telomeric association to 
replicative senescence is underlined by the fact that ectopic (re-) expression of telomerase is 
able to prevent many cell types from entering senescence (Bodnar et al, 1998; Vaziri & 
Benchimol, 1998; Yang et al, 1999). Conversely, telomerase inhibition in immortalised cells 
leads to the induction of replicative senescence (Ohmura et al, 1995). 
In mice, the effect of short telomeres on the ageing process was demonstrated in the 
TERC-/- mouse, a model deficient for active telomerase (Blasco et al, 1997). These mice lose 
regenerative capabilities of tissues and organs such as the hematopoietic system, 
reproductive organs, epithelia, liver, heart and blood vessels (Blasco et al, 1997; Franco et 
al, 2002; Herrera et al, 2000; Herrera et al, 1999a; Herrera et al, 1999b; Lee et al, 1998; Leri 
et al, 2003; Samper et al, 2002). This ultimately leads to premature ageing symptoms such 
as growth retardation, hair loss, skin ulceration and reduced wound healing resulting in a 
reduced mean and absolute lifespan (Garcia-Cao et al, 2006; Herrera et al, 1999b; Rudolph 
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Figure 5: Schematic depiction of the relation between 
telomere length aging and cancer. 
 
et al, 1999). Interestingly, in further generations of TERC-/- mice the longevity decreases 
continuously and the onset of the age related symptoms appear even earlier leading to 
infertility in the 3rd generation (in C57Bl6 genetic background) (Garcia-Cao et al, 2006; 
Herrera et al, 1999b). Further investigations revealed that TERC-/- mice are characterized by 
highly increased numbers of short telomeres that lack the possibility to form the protecting T-
loop. Subsequently, the critically short telomeres are recognised as DNA damage and DNA 
repair mechanisms are initiated causing chromosome fusions as seen in chapter 2.4. 
Strikingly, the re-expression of functional telomerase rescues premature telomere 
shortening, protecting from 
chromosomal fusions and the 
mentioned phenotypes (Samper et al, 
2001). Even though it was thought that 
adult stem cells cycle with a low 
frequency, they also suffer from 
telomere shortening in TERC-/- mice. 
Stem cells with shortened telomeres 
reveal lower tissue renewal capacities. 
Similarly to the differentiated cells, the 
premature ageing effects can be 
rescued by the reintroduction of 
telomerase (Donate & Blasco, 2011; 
Flores et al, 2005; Siegl-Cachedenier 
et al, 2007).  
 
3 . 8 . 1 .  T E L O M E R E  A S S O C I A T E D  D I S E A S E S  
Patients with defective telomerase and telomeres show premature aging that is often 
accompanied by diseases associated with telomere dysfunction.  
3.8.1.1. Dyskeratosis Congenita (DC) 
DC is a rare disease with a prevalence of 1 in 1’000’000. It is characterized by 
dystrophic nails, skin hyperpigmentation and oral leukoplakia, an epithelial dysplasia of oral 
mucosa (Carroll & Ly, 2009; Drachtman & Alter, 1995). During infancy, mucocutaneous 
disorders appear followed by bone marrow failure and aplastic anaemia that are usually fatal. 
Gradually, various premature aging symptoms such as pulmonary diseases, dental 
abnormalities, oesophagostenosis and alopecia can appear. On average, patients die before 
the age of 16 (Carroll & Ly, 2009; Drachtman & Alter, 1995). DC is linked to a telomerase 
dysfunction as many patients have been found to carry a mutation in one of the three main 
components of the telomerase complex (DKC1, TERT or TERC) (Carroll & Ly, 2009; 
Martinez & Blasco, 2011). Also telomere interacting proteins such as TIN2 have been shown 
to contribute to the disease (Savage et al, 2008). Mutations in these genes can lead to 
shortened telomeres, genomic instability and a higher incidence of sporadic cancer, all 
symptoms that are found in DC patients (Carroll & Ly, 2009). 
 
3.8.1.2. Acquired aplastic anaemia 
Acquired aplastic anaemia is a disorder characterized by a hypocellular bone marrow. 
The leukocytes in such patients show severely shorter telomeres if compared to age 
matched healthy individuals. This disease could be linked to mutations in TERT, TERC and 
the shelterin complex proteins TRF1, TRF2 and TIN2 (Carroll & Ly, 2009; Martinez & Blasco, 
2011; Savage et al, 2006). 
 
3.8.1.3. Idiopathic Pulmonary Fibrosis (IPF) 
IPF is a degenerative and rare lung disease where patients suffer from dyspnea, 
cough and an impaired gas exchange. IPF has a prevalence of 4 in 100’000 individuals and 
is likely to occur in DC patients. In 12% of the patients a mutation in the telomerase 
components TERT and TERC could be found (Armanios et al, 2007; Tsakiri et al, 2007).  
 
3.8.1.4. Telomeres and Cancer 
Telomere shortening, as seen in the TERC-/- mouse, has a tumor suppressing effect 
(Blasco et al, 1997; Gonzalez-Suarez et al, 2003; Gonzalez-Suarez et al, 2000). Critically 
short telomeres and/or loss of telomere binding proteins causes telomere uncapping and loss 
of telomere protection. Under p53/pRB competent conditions, this results in genomic 
instability activating the DDR cascade that forces the cell into cell cycle arrest or apoptosis 
(Fig. 5). In cells with p53 depletion, short telomeres contribute to chromosomal instability, a 
prerequisite for prone cells to transform (Deng et al, 2008). Interestingly, in 80 to 90% of all 
the human cancer, transformed cells acquire telomerase activity during tumorigenesis (Fig 
5). This counteracts telomere shortening in fast cycling cells and consequently increases 
cancer cell viability allowing a tumor to maintain telomeres stable; a hallmark of cancer 
(Bodnar et al, 1998; Hanahan & Weinberg, 2000; Shay & Wright, 2006; Shay & Wright, 
2011).  
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The ambiguous role of telomeres in cancer and tumor suppression is further underlined 
by the fact that models with facilitated telomere elongation (mainly by TERT overexpression) 
are more prone to spontaneous transformation, accentuating that telomere erosion over age 
is a relevant tumor suppressing property, limiting the proliferation potential of a transformed 
cell (Artandi et al, 2002; Canela et al, 2004; Cayuela et al, 2005; Gonzalez-Suarez et al, 
2001). Elevated susceptibility of spontaneous cancer in K5-TERT overexpressing mice 
(constitutively expressing TERT in stratified epithelial tissues) could be rescued by crossing 
with mice carrying an enhanced expression of p53, p16 and p19ARF tumor suppressors. 
Those mice not only had lower tumor susceptibility, but also showed a 40% increase of 
median lifespan and resistance for ageing-associated pathologies (Tomas-Loba et al, 2008). 
These findings show that for an organism it is a constant balancing act keeping the correct 
relation to telomere length; not favouring cancer prone cells with long telomeres but also 
counteracting early ageing phenotypes emerging from short telomeres. 
 
3.9 .  TH E  TELOM ER E R EPE AT  B IN D IN G  FAC T OR  1 
The murine TRF1 is a 56kD protein encoded on chromosome 1 in the band qA3. 
According to the consensus coding sequence project (CCDS), it consists of 10 exons and 
spans a distance of 37812 bases that are further transcribed, spliced and translated into a 
421 amino acid protein. The fully transcribed TRF1 protein is mainly recruited to the end of 
chromosomes where it binds as a dimer to the double stranded DNA of the telomeres. The 
full length protein contains four functional domains (Fig. 6). The amino end domain does not 
show an evolutionary conserved primary sequence, but in vertebrates it is characterized by a 
high density of acidic amino-acids giving the domain a low pH (pH~3). This domain shows 
the most marked difference to the homologue protein TRF2. The TRF2 protein has 
predominantly basic amino-acids in this position that force the telomeric DNA into a more 
condensed state, stabilizing the T-loop conformation. The acidic domain of TRF1 is followed 
by the TRF homology (TRFH) domain that is responsible for homodimerisation and 
interaction with the shelterin complex protein TIN2. Towards the C-terminus the protein 
contains the nuclear localisation motif as well as the highly conserved Myb-domain that 
allows the TRF1 protein sequence specific DNA binding to telomeres (Fig. 6) (Bianchi et al, 
1997; Broccoli et al, 1997; Fairall et al, 2001; Poulet et al, 2009; Poulet et al, 2011; Smith & 
de Lange, 1997). 
Figure 6: Murine TRF1 locus on top and protein structure on the bottom. N- to C-terminus: The 
acidic domain with a pH around 3; the TRF homology domain (TRFH) for protein-protein 
interaction; the nuclear localisation signal (NLS) and the Myb-domain, responsible for the telomeric 
localisation. 
 
The TRF1-DNA telomere binding efficiency can be regulated post-translationally by 
tankyrase 1 and 2 that poly-ADP-ribosylate TRF1 (Cook et al, 2002; Donigian & de Lange, 
2007; Smith et al, 1998). ADP-ribosylation releases TRF1 from the telomere making it 
accessible for polyubiquitination and degradation through the proteasomic pathway. This 
implies that the displacement of TRF1 allows a faster attachment of telomerase to the 
telomere (Chang et al, 2003; Lee et al, 2006). This suggestion is further strengthened by 
various over-expression assays demonstrating that TRF1 acts as a negative telomere length 
regulator (Ancelin et al, 2002; Munoz et al, 2009; Smogorzewska et al, 2000; van Steensel & 
de Lange, 1997). Another telomere length regulation mechanism emerges from the TRF1 
binding protein PIN2-interacting protein1 (PINX1). PINX1 is reported to be a telomerase 
inhibitor that binds to the TRFH domain of TRF1 and to the TERT subunit inhibiting its 
activity thereby counteracting telomere lengthening (Zhou & Lu, 2001).  Apart from the 
telomerase hindering effects of TRF1 another telomere shortening mechanism was 
suggested as the TRF1 overexpression-dependent telomere shortening was rescued by the 
ablation of the XPF-nuclease. This indicates increased XPF nucleolytic activity at chromosal 
ends in TRF1 overexpressing cells and is similar to what has been reported for the TRF2 
over-expression (Munoz et al, 2009; Munoz et al, 2005; Smogorzewska et al, 2000). 
Overexpressed TRF1 in addition co-localizes with BubR1 and Mad2, two spindle assembly 
checkpoint proteins preventing cells from undergoing aberrant mitosis (Munoz et al, 2009). 
On the other hand, complete TRF1 deletion in mouse leads to early embryonic 
lethality at the blastocyst stage between embryonic days E5-6. Rather interesting is the fact, 
that those telomeres do not show any telomere capping abnormalities or telomere length 
defects (Karlseder et al, 2003). If TRF1 ablation is induced later in development, TRF1 
underlines its important role in the maintaining of telomere capping (Martinez et al, 2009; 
Sfeir et al, 2009). The conditional knock-out, in vitro as well as in vivo, leads to a severe 
induction of telomere fragility as determined by increased occurrence of multitelomeric 
signals (MTS), sister chromatid fusions at the telomeres and chromosome concatenation 
  
In
tr
o
d
u
c
ti
o
n
 
(Martinez et al, 2009). This causes an increase of telomere dysfunction induced foci (TIFs), 
indicating the induction DNA damage response (DDR). The damage signalling at such 
aberrant telomeres is mediated via phosphorylated ATM and the ATM/ATR downstream 
checkpoint kinases CHK1 & CHK2 leading to the rapid induction of p53 and pRB mediated 
senescence that can, to a great extent, be rescued in a p53 null background (Martinez et al, 
2009).  
Such TRF1 deletion in stratified epithelia (TRF1lox/lox; K5-Cre) has been well 
characterized. These mice die perinatally and show severe skin degeneration effects such as 
hyperpigmentation, lack of mature hair follicles and missing sebaceous glands. Until 
postnatal day 6, these mice show compensatory preneoplastic lesions in all stratified 
epithelia. However, TRF1∆/∆; K5-Cre; p53-/- mice show a rescue of hair follicle stem cells, skin 
hyperpigmentation as well as increased survival, underlining that the observed phenotype is 
p53 mediated. In later stages, double deficient mice develop different telomere-associated, 
hyperproliferative epithelial abnormalities like oral leukoplakia and nail dystrophy (Martinez et 
al, 2009). These are characteristics also found in the telomere associated human diseases 
dyskeratosis congenita, aplastic anaemia and idiopathic pulmonary fibrosis (Armanios et al, 
2007; Mitchell et al, 1999; Tsakiri et al, 2007; Yamaguchi et al, 2005). As the uncapped 
telomeres induce genomic instability, it is not surprising, that long lived K5-Cre; TRF1∆/∆; p53-
/- mice develop spontaneous, invasive and genomically unstable squamous cell carcinomas 
(Martinez et al, 2009).  
The regulation of TRF1 is widely unclear although various binding sites for pluripotency 
transcription factors were reported (Loh et al, 2006). This goes along with the hypothesis that 
long telomeres in pluripotent cells would consequently require more TRF1 to cover the 
increased number of telomere repeats.  
The above mentioned findings show that TRF1 is preventing telomere-induced genetic 
instability in proliferating cells. In addition, they make TRF1 knock-out models valuable tools 
to study the molecular mechanisms underlying telomere-associated diseases that are 
caused by unprotected telomeres due to critical shortage or by telomere uncapping.  
3.10.  TELOM ER ES AN D  IPS  C ELLS  
 
3 . 1 0 . 1 .  W H A T  A R E  I P S  C E L L S  
Embryonic Stem (ES) cells are capable of differentiating into all somatic cell types and 
have an unlimited self-renewal capacity. Therefore, among all cells, they are thought to have 
the greatest potential for medicinal and research purposes. Nevertheless, ES cells have to 
be isolated from the inner cell mass of an embryo which, for humans is tightly regulated and 
limited in most countries.  Additionally, at the time ES cells differentiate they face the problem 
of augmented immunological incompatibility with a host organism due to an increase of the 
major histocompatibility complexes (MHC) (Fairchild et al, 2005). Therefore clinical use of ES 
cells is limited to tissues with a low immune response. Similar problems are faced with other 
methods generating undifferentiated cells such as somatic cell nuclear transfer into a 
fertilized oocyte or the cell fusion approach where a somatic cell and an embryonic stem cell 
are fused (reviewed in (Hochedlinger & Jaenisch, 2006)). 
Knowing the wide potential of undifferentiated cells in medicine and research, a huge 
effort was made to find a way to reprogram somatic cells to avoid the use of ES cells. In 
2006 Takahashi and Yamanaka reported a method of reprogramming murine fibroblasts 
through the expression of four known transcription factors. They demonstrated for the first 
time that lentiviral based expression of OCT4 (Octamer3/4), SOX2 (SRY box-containing 
gene 2), Krüppel-like factor 4 (KLF4) and c-MYC reprograms cells, as seen by their ES cell 
like morphology and properties (see next chapter). These reprogrammed cells were named 
induced pluripotent stem (iPS) cells (Takahashi & Yamanaka, 2006). A few months later, the 
same group was able to reprogram human fibroblasts using the same protein expressing 
cocktail, indicating that the signalling underlying pluripotency is an evolutionary conserved 
network (Takahashi et al, 2007). Many researchers were following these findings and 
additionally came up with different protein cocktails for reprogramming; including the finding 
that c-Myc is not required for reprogramming (Nakagawa et al, 2008; Wernig et al, 2008). 
As lentiviral integration sites are a potential oncological risk in the usage of iPS cells in 
therapies, current research is following on reprogramming techniques with non integrating 
methods such as the use of adenoviral vectors (Stadtfeld et al, 2008b) or microRNA 
(Subramanyam et al, 2011) bringing iPS cells closer to clinical use. Initial remarkable studies 
in mice could already show the wide potential iPS cells have in cell replacement treatments. 
Examples include the rescue of sickle cell anaemia (Hanna et al, 2007; Wang et al, 2009) or 
the Fanconi anaemia (Raya et al, 2009). 
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3 . 1 0 . 2 .  P R O P E R T I E S  O F  I P S  C E L L S  
Similar to ES cells, IPS cells grow in colonies on fibroblast feeder cells or gelatin coated 
dishes. They require a special culturing environment including the leukaemia inhibitory factor 
(LIF) and knockout serum replacement (KSR) (Bryja et al, 2006; Cheng et al, 2004; Nichols 
et al, 1990; Takahashi & Yamanaka, 2006). Under these conditions, iPS cells maintain a 
normal karyotype and pluripotency over numerous cell cycles and tissue culture passages. 
This was demonstrated by teratoma formation assays by subcutaneous injection of 
reprogrammed iPS cells in severe combined immunodeficient (SCID) mice. Like ES cell 
teratomas, well reprogrammed iPS cells initiate teratomas that contain differentiated tissues 
from all three germ layers (endoderm, mesoderm and ectoderm) (Takahashi & Yamanaka, 
2006). Another assay showing the ES properties of iPS cells is the aggregation of fertilized 
morulae with iPS cells in which competent iPS cells participate in chimerism and germline 
transmission (Okita et al, 2007; Stadtfeld et al, 2008a).  
IPS cells also show a similar gene expression pattern to ES cells initiated by the 
removing of tissue specific epigenetic patterns, leading to an ES cell like expression of the 
proteome (Maherali et al, 2007; Mikkelsen et al, 2008; Takahashi & Yamanaka, 2006; 
Wernig et al, 2008). In both cell types the transcription factor Nanog is upregulated by KLF4 
and the PI3K, MAPK and JAK/STAT pathways. These pathways are activated by Interleukin-
6 (IL-6) family cytokines including Leukaemia Inhibitory Factor (LIF), a factor that is essential 
in the iPS/ES culture medium for mice (Fig. 7). Nanog, OCT3/4 and SOX2 form a signalling 
loop for the mutual maintenance of expression. These three transcription factors are required 
to activate downstream pluripotency-associated genes. The feedback-loop can be 
interrupted by retinoic acid that inhibits OCT3/4 and leads to differentiation of the iPS cells; a 
protocol that is widely used to follow differentiation induced changes (reviewed in (Hanley et 
al, 2010)). 
 
Figure 7:  Cell signalling associated with the 
maintenance of pluripotency.  
The binding of IL-6 family cytokines to their respective cell 
surface receptors activates PI3K, MAPK and JAK/STAT 
pathways. The MAPK pathway is also stimulated by FGF4. 
Smad 2/3 signalling is activated in the presence of TGFβ 
family ligands. WNT signalling is enhancing OCT3/4 
expression and shares MYC as a common target with the 
JAK/STAT pathway. Krüppel-like factors and signals from 
the PI3K pathway stimulate the expression of Nanog. 
OCT3/4, SOX2 and NANOG form a signalling loop for the 
mutual maintenance and autregulate its expression. These 
three transcription factors also activate downstream 
pluripotency-associated genes including FGF4, UTF1, 
FBXO15, ZFP42 and FOXD3. Retinoic acid induces 
differentiation by inhibition of OCT3/4.  Adapted from 
(Hanley et al, 2010). 
 3.11.  TELOM ER ES IN  IPS  C ELLS  
After the introduction of iPS cells it became of great interest whether telomeres also 
acquire ES cell like characteristics such as elongated telomeres and a more open telomere 
chromatin structure. Indeed, similar to ES, iPS cells express high levels of telomerase. Active 
telomerase in post reprogrammed iPS cells drastically elongates telomeres to a length that is 
comparable to ES cells (Marion et al, 2009b). Moreover, telomeric chromatin structure of 
reprogrammed MEFs is altered during reprogramming. H3K9m3 and H4K20m3 
heterochromatic marks are decreased in iPS cells compared to their parental cells, leading to 
a more open and plastic structure of telomeres (Marion et al, 2009b; Meshorer et al, 2006). 
Of note, and in agreement with the longer telomeres, TERRA (telomeric RNA) levels are 
increased in iPS cells when compared to the parental cells. TERRAs are thought to be a 
negative regulator of telomere length possibly counteracting telomere elongation in iPS cells 
once telomeres have become hyperlong (Marion et al, 2009b; Schoeftner & Blasco, 2008).  
Cells with critically short telomeres have a decreased reprogramming efficiency 
indicating that there is a minimum telomere length necessary for efficient reprogramming 
(Marion et al, 2009b). Cells with critically short telomeres or missing shelterin components 
present high numbers of uncapped telomeres that give substrate to the DDR cascade that 
further initiates a p53 dependent cell cycle arrest, explaining the low reprogramming efficacy 
by genomic instability (Marion et al, 2009a). Abrogation of p53 bypasses the decrease in 
reprogramming in genomically unstable cells (Belmonte et al, 2009; Hong et al, 2009; Li et al, 
2009; Marion et al, 2009a; Tejera et al, 2010). 
 
3.12.  T ISSU E  STEM  C ELLS  
3 . 1 2 . 1 .  W H A T  A R E  T I S S U E  S T E M  C E L L S ?  
Embryonic stem cells are cells with pluripotent capacity; i.e. they are able to differentiate 
to all cell types following the differentiation of the blastocyst inner cell mass. Once these cells 
initiate this process, they are dedicated to only one cell lineage and lose the ability to 
differentiate into cells of different tissues. Further, in the adult organisms, only a low fraction 
of cells remain in a fairly undifferentiated state keeping their potential to differentiate into the 
various cell types of a tissue. These adult tissue stem cells are located in dedicated regions, 
called the stem cell niches. The niche creates a microenvironment that is able to control stem 
cell behaviour and maintaining the undifferentiated state as postulated already in 1978 by 
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Schofield, much before the first tissue stem cell could be isolated (Hsu & Fuchs, 2012; 
Schofield, 1978). In vivo and in comparison to other cells of the tissue, stem cells are mainly 
slow cycling, have the capacity to replenish themselves and give rise to more committed, uni- 
or multipotent cells downstream in the cell-lineage. Thereby, different adult tissues have 
different requirements. In fast renewing tissues such as the intestine, the epidermis and 
blood, stem cells are constantly in use as they need to replace the lost cells continuously 
(Fuchs, 2009; Li & Clevers, 2011). Other tissues such as muscles and the brain are dormant 
and their stem cells are only activated upon stimuli such as learning or injury. This diverging 
stem cell behaviour is also found in cancer stem cells where they have been found to cycle in 
a fast and/or slower, dormant manner. New evidence also suggests slow and faster cycling 
stem cell in high turnover tissues (Hsu & Fuchs, 2012).  
3 . 1 2 . 2 .  T E L O M E R A S E  I N  T I S S U E  S T E M  C E L L S  
A basic level of active telomerase is found in tissue stem cells but its activity is not 
sufficient to maintain the telomere length over the organism lifespan (Collins & Mitchell, 
2002). The erosion of telomere length is thought to be one of the underlying mechanisms of 
aging. The rationale is that “old” stem cells that have accumulated DNA damage have 
lowered proliferation potential. The subsequent loss of production of sufficient progenitors 
leads to the aged appearance of tissues. This, on the other hand reduces the risk of cancer 
induced by cells with genomic instability, explaining the advantage of a non-constitutively 
active telomerase (reviewed in (Collins & Mitchell, 2002; Shay & Wright, 2011)). The 
expression of active telomerase was found to be regulated to a certain extent by the WNT/β-
catenin signalling that directly and indirectly (via KLF4) initiate TERT expression (Hoffmeyer 
et al, 2012). However, the precise regulation of the telomerase in tissue stem cells remains 
widely elusive to date. 
Signalling pathways of tissue stem cells are widely understood. However, their location 
and valuable tissue stem cell markers are still not well defined. Therefore this field is under 
constant development. Below, I describe current knowledge concerning the skin and the 
small intestine stem cells. 
 
3 . 1 2 . 3 .  S K I N  S T E M  C E L L S  A N D  T H E  H A I R  F O L L I C L E   
Hair follicles, the epithelial structure that gives rise to hair, develop within the early 
ectoderm when inductive and repressive signals allow the budding of hair follicle cells into 
the subcutis. Once established, the interfollicular epidermis and the sebaceous gland (SG) 
are subjected to constant self renewal, whereas the cells of the hair follicle (HF) lineage cycle 
Figure 8: Hair follicle cycle and stem cell niches in the hair follicle 
A: Simplified hair cycle depiction. Hair follicles grow synchronously; they cycle from the telogen state 
into anagen and then with apoptosis in the lower 3
rd
 of the hair follicle they regress in catagen ending 
up in the resting telogen phase (Fuchs, 2007). B: Schematic depiction of a telogen hair follicle. 
Visible is its anatomy and the various stem cell lineages, niches and locations (Woo & Oro, 2011). 
A B 
between growth (anagen), involution (catagen) and resting (telogen) phases (Fig. 8A). The 
latter (HF cells) require therefore an extensive tissue expansion in anaphase whereas in 
catagen and telogen the cell turnover is minimal. 
For a long time, using BrdU label retaining experiments as a trait to localize stem cells, 
it was believed that skin stem cells were located exclusively in the (telogen-) bulge region of 
the hair follicle.  For above described reasons, the HF lineage stem cells retained BrdU for 
over two hair cycles and were believed to be the only cells in the hair follicle and skin with 
stemness potential (Cotsarelis et al, 1990). Recent findings however, have led to the 
development of a different view. Lineage tracing experiments, where whole tissues are 
rebuilt from one cell type widened the number of niches and initiated a new concept of adult 
skin stem cells. It is now believed, that the hair follicle contains a variety of stem cells (Fig 
8B). These stem cells, are divided into 3 pools (epidermal, sebaceous (SG), and hair follicle 
(HF)) and contribute to their distinct cell lineages in the hair follicle, replenishing cells that are 
lost by daily use. (Alonso & Fuchs, 2006; Cotsarelis et al, 1990; Fuchs & Horsley, 2008; Woo 
& Oro, 2011). We now know that all stem cells of the three different compartments, as seen 
in figure 8B (depicted is a telogen state hair follicle), can give rise to fully functional hair 
follicles, generating all the structures, including the corresponding niches with their stem 
cells. This is important in case of homeostasis disruption such as injury where whole stem 
cell pools might be lost. The different stem cells can be distinguished either by morphology or 
with help of different markers as seen in figure 8B (Barker et al, 2007; Fuchs & Horsley, 
2008; Jensen et al, 2009; Levy et al, 2007; Snippert et al, 2010).  
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Figure 9: Hair follicle with a heat map 
according to the telomere length of each 
cell. The warmer the colour, the longer 
the telomeres per nuclei. The longest 
telomeres are found in the epidermal, 
sebaceous and hair follicle stem cell 
niches, here named as “Hair bulge”. 
(Flores et al, 2008) 
 
3 . 1 2 . 4 .  T E L O M E R E S  I N  S K I N  S T E M  C E L L S  
In 2008 Flores et al. established a new method to map the number of telomere repeats 
in a nucleus. The technique named “telomapping”, allows the comparison of telomeres within 
a tissue and therefore, to distinguish between nuclei with variable telomere lengths. In this 
method, telomeres are labelled by a CY3 fused telomeric-PNA probe as used in the 
established Quantitative-Fluorsecent In Situ Hybridisation (Q-FISH) telomere measurement 
techniques (see materials and methods). The average CY3 intensity measured for each 
nucleus is used to generate a heat map, representing the telomere length with a colourcode. 
The colder colours (green) depict nuclei with short telomeres and the warmer colours (red) 
correspond to long telomeres (FIG. 9).  
Due to a lower cycling frequency and residual telomerase activity, cells in the adult stem 
cell niche are commonly those with the longest telomeres in a tissue. This effect allows the 
telomapping technique to localize adult stem cell niches, independent of bona-fide stem cell 
markers (Flores et al, 2008). In the skin, the longest telomeres were found in the bulge 
region, whereas the bulge region in the original publication was including the stem cells from 
the HF-, the SG- as well as some stem cells of the epidermal lineage (Fig 8 & 9). Telomere 
length decreased from these cells towards the bulb and the infundibulum with the shortest 
telomeres in the outer layers of the interfollicular epidermis (Fig. 9) (Flores et al, 2008). As 
visible in the above images the warm colours go along with stem cell markers (Lrig1, Lgr6, 
Blimp1, MTS24,...) that were recently established as seen in Fig. 8B (reviewed in  (Woo & 
Oro, 2011). 
 Figure 10: Intestinal crypt/villi 
Organisation of an intestinal crypt where the Lgr5+ 
stem cells are depicted in yellow, interspersed with 
paneth cells (green). Further up are the +4 to +7 
positioned stem cells that still express low amounts of 
Lgr5 followed by the transient amplifying (TA) 
compartment. Depicted in orange are the cells of the 
villi.  
 
3 . 1 2 . 5 .  S M A L L  I N T E S T I N E  
To maintain a constant nutrient uptake the small intestine in mammals completely 
renews itself every 3 to 5 days, putting the intestinal epithelium under high replicative 
pressure (Hsu & Fuchs, 2012). This high turnover is sustained by intestinal stem cells. It has 
been shown that different types of stem cells are responsible for the tissue homeostasis. On 
the one hand, there are cycling stem cells that express the G-protein-coupled receptor LGR5 
(Fig. 10). Lineage tracing experiments have shown that these cells have the potential to give 
rise to complete crypts and villi (Barker et al, 2007). On the other hand, there are the slow 
cycling, BrdU retaining stem cells localized above the strong LGR5 positive cells still 
expressing low amounts of LGR5 (position +4 to +7 from the crypt bottom). Not all the cells 
of this region are stem cells but lineage tracing experiments with various stem cell markers 
demonstrated that many of those cells are capable of establishing whole villi and crypt 
structures. (Montgomery et al, 2011; Sangiorgi & Capecchi, 2008; Takeda et al, 2011). This 
makes the LGR5 positive stem cells dispensable (Tian et al, 2011).  
 
 
 
 
 
The lack of stem cell hierarchy and the functional equivalency led to the hypothesis that 
the slower cycling cells are mainly a reserve pool in case of tissue injury, whereas the faster-
cycling Lgr5+ cells are of main importance for small intestine homeostasis (Hsu & Fuchs, 
2012). Strengthening this theory is the fact that LRIG1, a bona-fide stem cell marker that was 
described in skin stem cells, is also present in the small intestine (Jensen et al, 2009; Wong 
et al, 2012). LRIG1 is a negative feedback regulator of ErbB which itself is driving cells 
towards differentiation. LRIG1 is therefore essential for maintaining stem cells multipotent 
(Gur et al, 2004; Jensen et al, 2009; Laederich et al, 2004; Wong et al, 2012). In the small 
intestine, as one of the first markers, it resembles both the cycling compartment and the slow 
cycling compartment of stem cells showing that both cell types have stem cells properties 
(Wong et al, 2012).  
  
 
Figure 11: Telomap and telomerase expression of intestinal crypts 
(A) Shown in this telomap are the nuclei with the least telomeric repeats (colder colours) in the 
villi epithelium as well as in nuclei at the crypt bottom. The crypt that is divided into transient 
amplifying- and stem cells shows longer telomere with the highest amounts of telomeric repeats 
in the stem cells (warm colours) (Flores et al, 2008). (B)  Percentages mTERT-GFP expressing 
cells in the small intestine by their position in the crypt and percentage of the total number of GFP 
positive cells (Montgomery et al, 2011). This corresponds with the general understanding of the 
slow cycling stem cells above the strong LGR5 positive, cycling stem cells. 
 
A B 
3 . 1 2 . 6 .  T E L O M E R E S  I N  I N T E S T I N E  S T E M  C E L L S  
In the small intestinal epidermis, telomeres were compared using the telomapping 
technique (described in point 3.12.4). Also in this tissue the cells that were the most 
differentiated i.e. paneth and villi cells had the shortest average telomere length. They are 
followed by the transient amplifying cells and the stem cells with the longest telomeres 
(around position +4; Fig 11A) (Flores et al, 2008). This is in agreement with the general 
understanding of intestinal tissue homeostasis at the time this paper was published. The 
findings from Flores et al. are also in agreement with the findings that telomerase expressing 
cells are situated above the strong LGR5 expressing cells (Fig. 11B) (Montgomery et al, 
2011). New insights into the intestinal tissue stem cell biology, especially the detection of the 
cycling LGR5 positive stem cells, interspersing the differentiated paneth cells, were not taken 
into account in the publication of Flores et al.. A telomere comparison was made in this 
thesis and is visible in the result part (result Fig. 24B&D). 
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4.  A I M S  O F  T H E  ST U D Y  
 
 
 
 
1. Generate and characterize the phenotype of an eGFP-tagged TRF1 mouse model. 
2. Study the abundance and distribution of eGFP-TRF1 in different tissues of the murine 
organism and its localisation within different tissues with respect to the telomere 
length. 
3. Study the potential of TRF1 as a stemness indicator and its role in reprogramming. 
4. Study possible mechanisms by which TRF1 can be regulated. 
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5.1 .  TRF1  D EC RE ASES  D ISPR OP OR TI ON ALL Y  OVER  AG E  
Upon analysis of human and murine TRF1 in the interfollicular epidermis a 40% 
decrease of its expression from young to old individuals was observed (Figure 1A-D). As 
TRF1 binds the double stranded DNA portion of the telomere one would expect that the 
erosion of telomeres and the decrease of TRF1 seen at telomeres would occur 
approximately at the same rate. Interestingly, if compared to the telomere length decrease 
previously seen in mice (Flores et al, 2008), the decrease of mTRF1 is disproportional 
(mTRF1 decrease: 40% vs. telomere decrease: 2-3% (Flores et al, 2008)). Also in human, 
within the same tissue sections used for measuring the TRF1 expression, the telomere 
intensity measured by a tissue Q-FISH only decreased 16% (Figure 1E). This indicates that 
the amount of TRF1 bound to telomeres does not solely depend on telomere length and that 
its regulation might have further, yet unknown biological functions.  
Figure 1: TRF1 decreases 
disproportionally and more 
than telomere length 
throughout human and 
mouse aging. 
TRF1 quantification and 
representative pictures of 
murine (A&B) and human 
(C&D) tissue samples of back 
skin interfollicular epidermis of 
young, middle aged and old 
individuals. Ages are indicated. 
In both mouse and human, the 
decrease of TRF1 intensities is 
around 40%. Indicated is the 
average nuclear TRF1 
intensity. Measurements of the 
telomere intensity per nucleus 
(of the same human tissue 
samples) showed under-
proportional telomere erosion 
(16%) over age if compared to 
TRF1 expression (E). 
Statistical comparisons were 
done using one tailed student 
t-test. 
A B 
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Figure 2: The eGFP-TRF1 locus  
(A) Schematic representation of the TRF1 and the eGFP-TRF1 allele. (B) Confirmation of the different 
alleles by PCR analysis. F/R: forward/reverse primer for PCR analysis, Neo: neomycin cassette. 
 
5.2 .  GEN ER ATI ON  OF  M IC E  WI TH  A K N OC K - IN  EGFP-TRF1  AL LELE   
To further study the relation of TRF1 to telomere length and other possible roles of TRF1, 
we designed an eGFP-TRF1 knock-in construct from which a mouse was generated 
(materials and methods). The construct consists of an eGFP-tag inserted directly behind the 
ATG start-codon in the first exon of the TRF1 locus (Fig. 1A). The neomycin selection 
cassette was flanked by loxP sites and an additional crossing step with CMV-CRE mice was 
used to generate the eGFP-TRF1 allele (Fig. 2A).  
 
Crosses between heterozygous knock-in allele carrying mice revealed that wild-type 
and heterozygous eGFP-TRF1+/KI mice were born following Mendelian ratios (Fig 3A). They 
are viable and fertile and show no overt phenotypes previously related to TRF1 loss of 
function such as, loss of skin hair follicles, growth retardation and hyperpigmentation (Fig. 
3B-C); (Martinez et al, 2009). Nevertheless, we failed to obtain viable mice of the eGFP-
TRF1KI/KI genotype, indicating embryonic lethality associated to this allele. Embryonic lethality 
occurred around day E13.5, as only 6% of the viable embryos were of the eGFP-TRF1KI/KI 
genotype versus the 25% expected ratio from eGFP-TRF1+/KI crosses (Fig. 3A). As complete 
loss of function of TRF1 in mice leads to early embryonic lethality at the blastocyst stage 
(Karlseder et al, 2003), the observed late embryonic lethality of homozygous eGFP-TRF1KI/KI 
embryos suggests that the eGFP-TRF1 allele is hypomorphic and the resulting fusion protein 
is partially functional.  
Complete, conditional loss of function in of TRF1 was shown to lead to end-to-end 
fusions and presence of telomeres with multitelomeric signals (MTS) related to increased 
telomere fragility, as well as to drastic activation of a persistent DNA damage response 
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Figure 3: Phenotypes of the eGFP-TRF1 allele. 
(A) Birth-, MEFs- and gender-ratios (absolute numbers in brackets). Note the disproportional 
percentage of eGFP-TRF1
KI/KI
 MEFs and the fact that no eGFP-TRF1
KI/KI
 mouse is born. Wild-type and 
eGFP-TRF1
+/KI
 MEFs and mice correspond to the expected Mendelian ratio. (B) Weight alterations over 
age are not detected in eGFP-TRF1
+/+ 
and eGFP-TRF1
+/KI
 mice (male and female). Statistical 
calculations are done by linear regression F-Function for intercept and elevation. (C) Tail-pigmentation 
alterations could not be detected between wild-type and eGFP-TRF1
+/KI
 mice. Error bars, SEM. 
Statistical comparisons were done using two tailed student t-test. (D & E) Growth- and senescence-
curves (senescence activated βgal) of eGFP-TRF1
+/+
, eGFP-TRF1
+/KI
 and eGFP-TRF1
KI/KI
 MEFs 
(E11.5). No significant differences between eGFP-TRF1
+/+
 and eGFP-TRF1
+/KI
 MEFs are seen. Statistic 
comparisons with eGFP-TRF1
KI/KI
 was not possible due to insufficient MEF harvest. MEF passage 
number=2; error bars, SEM. Statistical comparisons were done using two sided student t-test. 
 
D E 
(DDR) at chromosome ends, which fully impairs cell division (Martinez et al, 2009; Sfeir et al, 
2009). In line with this, although eGFP-TRF1KI/KI MEFs are able to divide in vitro (Fig. 3D), 
they show decreased proliferation rates and slightly increased senescence-associated -gal 
staining if compared with wild-type and heterozygous cells (Fig 3E), underlining the expected 
hypomorphic phenotype (Martinez et al, 2009; Sfeir et al, 2009).  
 
 
A B C 
Figure 4:  Elevated telomeric fragility 
in the absence of an increased DDR 
activation at eGFP-TRF1
KI/KI
 
telomeres.  
(A) Detection of telomere fragility in 
MEFs by telomeres stained with a 
telomeric FISH-probe. Increased 
numbers of multitelomeric signals 
(MTS) and sister chromatid type 
fusions (SCF) (B) are found in the 
eGFP-TRF1
KI/KI
 MEFs. (C) Yellow 
arrows in the representative images 
highlight MTS (top) and sister 
chromatid type fusions (bottom). Blue: 
dapi; red: telomers. (D) DNA-Damage 
Response (DDR) analysis by 53BP1 
atibody in MEFs.  Neither the 
percentage of 53BP1 positive/damaged 
cells nor the number of telomere 
dysfunction induced foci (TIF) (E) are 
significantly altered through the 
genotypes. Yellow arrows in 
representative pictures highlight TIFs, 
corresponding to the indicated 
genotype.  Blue, dapi; red, 53BP1; 
green, telomeres. MEF passage 
number=2; error bars, SEM; Statistical 
comparisons were done using two 
sided student t-test. 
  The lower proliferation rates in eGFP-TRF1KI/KI MEFs are concomitant with increased 
telomere fragility in these cells. This includes slightly augmented frequencies of sister 
telomere fusions (1-2 sister chromatid fusions per metaphase, a frequency that is 10-fold 
lower than that for a complete TRF1 abrogation) and increased frequencies of multitelomeric 
signals, to a level that is similar to TRF1-null MEFs (Fig. 4 A-C) (Martinez et al, 2009).  
However, this degree of telomere dysfunction in eGFP-TRF1KI/KI MEFs did not lead to a 
persistent DDR activation as indicated by similar frequencies of 53BP1-positive cells and by 
53BP1 foci co-localizing with telomeres (telomere dysfunction induced foci, or TIFs) in all 
three genotypes (Fig. 4 D&E). The fact that expression of the eGFP-TRF1 fusion protein 
does not lead to a persistent DDR activation is likely to reflect the largely normal telomere 
capping function of the fusion protein as indicated by very low frequencies of sister-chromatid 
end-to-end fusions in eGFP-TRF1KI/KI MEFs. 
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Figure 5.  eGFP-TRF1 protein is 
nuclear and localizes to telomeres.  
(A) Expression of eGFP-TRF1 fusion 
protein in living eGFP-TRF1
+/KI
 and 
eGFP-TRF1
KI/KI 
MEFs (passage 2). 
Top panels: eGFP-TRF1 fluorescence 
including red, contrasted bright field 
picture on the bottom to determine 
nuclear localization (nuclei are 
indicated by the dotted line). (B) Co-
localization studies between the 
indicated shelterin proteins TRF1, 
RAP1 and TPP1 with eGFP-TRF1 in 
eGFP-TRF1
+/KI 
MEFs (passage 2). 
Green, eGFP-TRF1; red, 
immunostained shelterins with 2
nd
 
antibodies labelled with Cy3 (TRF1 & 
Rap1) or A555 (TPP1).  
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5.3 .  TH E  EGFP-TRF1  FU S I ON  PR OTE IN IS  N U C LE AR  AN D  TR AC K S 
TELOM ER ES IN -V IVO  
The largely normal telomere capping in eGFP-TRF1KI/KI MEFs suggests that the fusion 
protein is able to bind and protect telomeres. To address this, we determined whether the 
expression of the eGFP-TRF1 fusion-protein was nuclear and co-localized with telomeres. 
As expected, we detected eGFP expression within the nuclei of living MEFs by confocal 
microscopy in both heterozygous- and homozygous-KI cells but not in wild-type cells (Fig. 
5A). Furthermore, eGFP expression co-localized with TRF1 and the shelterin proteins RAP1 
and TPP1, as indicated by double immunofluorescence with antibodies against these 
proteins in eGFP-TRF1+/KI MEFs (Fig. 5B). Together, these results indicate that the eGFP-
TRF1 fusion protein is expressed in the nucleus and localizes to telomeres. This can be used 
as a new tool to track TRF1 expression as well as telomeres in vivo by using direct 
fluorescence. See below (chapter 5.4) for additional data with induced pluripotent stem (iPS) 
cells showing that eGFP-TRF1 is able to accomplish the known interactions with the 
members of the shelterin complex and that it is able to bind to telomeric DNA-repeats.  
 
 
 
 
 
 
 
 
 
 
 
 
C 
Figure 6.  Generation of eGFP-TRF1 iPS cells and chimeras 
(A) Colony forming efficiency of reprogrammed MEFs normalized to WT. Alkaline phosphatase positive 
iPS colonies per optical field were counted. The efficiency is lowered in the eGFP-TRF1
KI/KI
 MEFs by 
around 45% whereas the WT and heterozygous MEFs do not show a significant alteration. Error bars, 
SEM; statistical comparisons, using two sided student t-test. (B&C) Numbers and representative images 
of chimeric mice obtained from morulae aggregation (HSD:ICR (CD-1)) with iPS cells of the indicated 
genotype. In the case of eGFP-TRF1
KI/KI 
iPS cells, only one chimeric mouse was obtained showing low 
chimerism. For the other genotypes we obtained chimeric mice with high chimerism. 
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5.4 .  H IGH  TRF1  EXPRESSI ON  IS  ASS OC I ATED  TO  IN D U C TI ON  OF  
PLU R IPOTEN C Y IN  I N D U CED  PLU R IPOTEN T STEM  ( IPS)  C ELLS   
To address the regulation of TRF1 expression during nuclear reprogramming and 
pluripotency with active telomerase, we generated iPS cells from MEFs of the different 
genotypes. The efficacy of reprogramming was lowered in the homozygous knock-in 
whereas WT and heterozygous MEFs had similar efficiency (Fig. 6A).  Even though the KI/KI 
genotype led to a lower reprogramming efficacy, iPS cells from the three genotypes gave rise 
to chimeric mice upon morulae aggregation. However, the amount of chimerism in the eGFP-
TRF1KI/KI aggregates was much lower compared to wild-type and heterozygous (Fig. 6 B&C). 
On the other hand, KI/KI cells were capable of forming differentiating teratomas (see chapter 
5.7). These results indicate that the eGFP-TRF1KI/KI iPS cells are pluripotent even though the 
parental MEFs show mild telomere fragility phenotypes and a lower percentage of 
chimerism.  
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 We next performed a Chromatin Immunoprecipitation (ChIP) analysis in iPS cells to 
confirm that the eGFP-TRF1 fusion protein could bind telomeric repeats. We found, using 
eGFP specific antibodies, that eGFP-TRF1 was located at telomeric chromatin in both 
heterozygous eGFP-TRF1+/KI and homozygous eGFP-TRF1KI/KI iPS cells but absent from 
wild-type iPS telomeres (Fig. 7A). As expected, in the heterozygous eGFP-TRF1+/KI cells 
around half the amount of telomeric repeats were detected by ChIP when compared to 
eGFP-TRF1KI/KI iPS cells (Fig. 7B). To address whether expression of eGFP-TRF1 could 
interfere with the expression of the untagged TRF1 allele, we analyzed the levels of wild-type 
TRF1 in the heterozygous eGFP-TRF1+/KI iPS cells by western blot. As shown in Fig. 7C, 
expression of the eGFP tagged protein does not affect endogenous TRF1 expression (for 
quantitative western blot analysis, refer to Fig 8A&B). In order to further test the in vivo 
functionality of the eGFP-TRF1 protein when compared with the untagged TRF1 protein, we 
performed an immunoprecipitation using anti-GFP antibody in eGFP-TRF1KI/KI, eGFP- 
TRF1+/KI, and eGFP- TRF1+/+ iPS cells and analyzed the isolated protein complexes by mass 
spectroscopy. This proteomic analysis showed that the telomere constitutive proteins TPP1, 
RAP1, TRF1, TIN2, and POT1 (de Lange, 2005) were specifically coimmunoprecipitated in 
both, the knock-in homozygous and heterozygous iPS cells (Fig. 7C). These results clearly 
indicate that the eGFP-TRF1 protein interacts with the telomeric repeats (shown by the ChIP 
analysis: Fig. 7D) and with other members of the shelterin complex that are known to be 
pulled down together with TRF1.  
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Figure 7. Chromatin immunoprecipitation (ChIP) with iPS cells. 
(A) Chromatin immunoprecipitation (ChIP) was performed with iPS cells of the indicated genotypes 
using antibodies against eGFP, TRF1 and H3 (control). Immunoprecipitated material was transferred to 
a nitrocellulose membrane and probed with a 1.6 kb telomeric probe (upper panel) and with a mouse 
major satellite probe (lower panel). (B) Quantification of ChIP values for telomere and centromere 
repeats, as indicated. The amount of immunoprecipitated DNA was normalized to the pre-immune serum 
(input). n= number of independent iPS clones used. Error bars, SEM; statistical comparisons, using two 
sided student t-test. (C) Western-blot analysis of KI/KI, KI/+, and +/+ eGFP-TRF1 iPS cells. Note that the 
anti-TRF1 panel shows both eGFP-tagged and non-tagged TRF1 protein. The anti-GFP panel indicates 
that eGFP-TRF1 band is specific. Cohesin SMC1 was used as a loading control and molecular weights 
are indicated in the right part of the panels. (D) Schematic representation of the coimmunoprecipitation 
and mass spectroscopy proteins identification experiment and selected results of shelterin proteins. All 
identified peptides corresponding to shelterin proteins are indicated together with their coverage 
percentage, peptide spectrum matching (PSM) and the number of identified peptides (Peptides) in the 
eGFP-TRF1
KI/KI
 iPS, the eGFP-TRF1
+/KI
 iPS and in both iPS indicated as “total”.  
 
  
 
 We also addressed whether TRF1 expression itself and that of the eGFP-TRF1 fusion 
protein was regulated during reprogramming. To this end, we performed western blotting 
analysis where we found that endogenous TRF1 protein expression is highly increased, in 
wild-type iPS cell clones compared to their parental MEFs (Fig. 8A&B). The increase of the 
TRF1 expression associated to reprogramming was in the same range as that of the 
pluripotency genes Oct3/4 and Nanog, suggesting that TRF1 may be related to induction of 
pluripotency (Fig. 8A&B). Western blotting analysis also showed induction of endogenous 
TRF1 in heterozygous eGFP-TRF1+/KI iPS, although to lower levels than eGFP-TRF1+/+ iPS 
cells owed to the presence of a single copy of the endogenous TRF1 gene, and was 
undetectable in homozygous eGFP-TRF1KI/KI iPS cells (Fig. 8A&B). Inversely, the eGFP-
TRF1 protein was highly expressed in eGFP-TRF1KI/KI iPS cells, to around half the levels in 
heterozygous eGFP-TRF1+/KI iPS cells, and was undetectable in wild-type iPS cells (Fig. 
8A&B). These results were also confirmed by FACS analysis, which showed that the eGFP-
intensity in eGFP-TRF1KI/KI is approximately two fold higher compared to that seen in eGFP-
TRF1+/KI (Fig. 8C left).  FACS analysis also confirmed similarly high Nanog expression in iPS 
cells of the three genotypes (Fig. 8C right), supporting their pluripotency.  
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Figure 8. TRF1 gets highly upregulated during reprogramming  
 (A&B) Western blotting against eGFP, TRF1, Nanog, OCT3/4 and Actin (loading control) of nuclear 
fractions of passage 3 parental MEFs (par.) and three independent iPS clones (passage 5) derived from 
them. Note that not all the iPS clones are perfectly reprogrammed and therefore show a different 
proteome, visible in wild-type iPS clone 2 were TRF1, Nanog and OCT3/4 show lower expression. 
Normalization was performed by division of the intensity integral of specific bands by the intensity 
integral of the loading control (Actin). Error bars, SEM; statistical comparison: two sided student t-test. 
(C) FACS analysis of iPS cells (passage 7) of the indicated genotype shows similar results as obtained 
by western blotting (left). Nanog quantification of fixed iPS cells shows that the Nanog expression is not 
altered in the different genotypes. Red, eGFP-TRF1
+/+
; Blue, eGFP-TRF1
+/KI
; Green, eGFP-TRF1
KI/KI
; 
Grey, eGFP-TRF1
+/KI
 without 1
st
 AB. Error bars, SEM; statistical analysis by two sided student t-test. 
  
 
 
 
 
 
 
 
 
 
 
 
In summary, both endogenous TRF1 and the knock-in eGFP-TRF1 expression are 
dramatically activated upon induction of pluripotency, in a fashion that resembles that of the 
Oct3/4 and Nanog pluripotency genes. The high expression of Nanog and OCT3/4 in eGFP-
TRF1KI/KI iPS clones is in agreement with successful generation of chimeric mice from these 
cells (Fig. 6 B&C), and further supports generation of pluripotent iPS cells expressing 
fluorescent eGFP-TRF1.  
A B 
C 
5.5 .  EGFP-TRF1  LEVELS  D O  N OT  C OR R EL ATE  W ITH  TELOM ER E 
LEN GTH  D U R IN G  IN D U C T ION  OF  PLUR IPOTEN C Y  
 Previous work showed that during the generation of iPS cells telomerase is activated 
and telomeres undergo a net telomere elongation, which continues post-reprogramming until 
reaching the hyper-long telomeres of ES cells (Marion et al, 2009b).  To address whether 
eGFP-TRF1 fluorescence correlated with telomere length in vivo, we determined telomere 
length at different passages of iPS cells by using the telomeric Q-FISH technique directly on 
fixed iPS colonies. IPS cells (P7) from all the three genotypes were able to elongate 
telomeres to a similar extent compared to the telomeres of corresponding parental MEFs 
(Fig. 9A-C). Strikingly, however, while wild-type and eGFP-TRF1+/KI telomeres continued 
growing with increasing passages until reaching hyper-long ES cell telomeres at passage 36, 
the telomeres of eGFP-TRF1 homozygous iPS cells ceased to further elongate between 
passage 7 and 16 (Fig. 9C). The inability of eGFP-TRF1KI/KI iPS cell telomeres to show 
further elongation might be related to increased telomeric aberrations in this genotype, 
mostly consisting of MTS, or may suggest a role of TRF1 in telomerase recruitment which is 
partially impaired by the eGFP-TRF1 fusion protein. In this regard, TPP1, a TRF1-interacting 
protein, was previously described to be required for telomerase-mediated telomere 
elongation during reprogramming (Tejera et al, 2010). These results highlight the importance 
of TRF1 for telomere length maintenance in vivo, and could provide a mechanistic 
explanation for the short telomere phenotype associated to some human diseases linked to 
putative defects in shelterin function (Savage et al, 2008; Savage et al, 2011).  
 Next, we measured the eGFP-TRF1 intensity per telomere and per nucleus to 
address whether it was directly correlated with telomere length changes during 
reprogramming. No linear correlation between telomere length and eGFP intensity was 
observed. In particular, while telomere length increased by about 1.7-fold when comparing 
MEFs with iPS cells at passage 7 (Fig. 9B), the eGFP intensity increased by >20-fold at this 
point (underestimating the eGFP intensity by saturated detection due to weak signal in the 
parental clones and 2D analysis) (Fig. 9E). Furthermore, while eGFP-TRF1 levels were 
maintained stable from passage 7 onwards, telomeres kept elongating until passage 36 (Fig. 
9B,C,E,F). This suggests that increased TRF1 level at the induction of pluripotency precedes 
telomere elongation, again in line the notion that elevated TRF1 levels are characteristic of 
the pluripotent state. These results are in accordance with the findings in figure 1, where 
TRF1 levels were shown to decrease independent of telomere shortening over age. 
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Figure 9. Defective telomere length maintenance in eGFP-TRF1 homozygous iPS cell clones. 
(A) Representative images of parental MEFs (passage 3) and iPS cells of indicated genotype and 
passages, labelled with a telomeric Q-FISH probe. Pictures were enhanced equally for better visibility. 
Blue, Dapi; red/grey, tel-PNA-Cy3 probe. (B) Analysis of average telomere fluorescence per telomere of 
the indicated MEFs (passage 3) and increasing passages of corresponding iPS cell clones. ES cells at 
passage 9 were included as controls. Statistical comparisons were done using two sided student t-test. 
Error bars, SEM. (C) Analysis of average telomere fluorescence per nucleus of the indicated MEFs 
(passage 3) and increasing passages of corresponding iPS cell clones. Wild-type ES cells at passage 9 
were included as controls. Statistical comparisons were done using two sided student t-test. Error bars, 
SEM. (D) Representative image of parental MEF (passage 3) and iPS cells of indicated genotype and 
passages analyzed for eGFP-TRF1. Pictures were enhanced equally for better visibility. Blue, Dapi; 
green/grey, eGFP-TRF1 fluorescence. (E, F) Analysis of the relative eGFP-TRF1 expression in parental 
MEFs (passage 3) and iPS cells of the corresponding genotype and passage number. Intensity of eGFP-
TRF1 per telomere spot (E) and per nucleus (F) was measured. Statistical comparisons were done using 
two sided student t-test. Error bars, SEM. ES at passage 9 are included as controls. 
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Figure 10. TRF1 is uncoupled from telomere elongation. 
(A&B) TRF1 is highly over expressed in iPS cells, even in the absence of telomere elongation. (A) 
Expression of TRF1 in wild-type and Tpp1MEF- and iPS cells as detected by western-blot. Note that 
TRF1 expression is highly increased in iPS cells if compared to parental MEF, even in Tpp1 iPS cells 
that do not elongate telomeres during reprogramming. SMC1 was used as a loading control for nuclear 
extract. (B) Quantification of TRF1 from A, relative to SMC1. Error bars, SEM. n= independent iPS 
clones. 
 
A B 
 To confirm our results and to exclude analysis artefacts, we studied TRF1 protein 
levels during reprogramming of MEFs deficient for TPP1 previously shown by our lab to fail 
to elongate telomeres in the process of generation of iPS cells (Tejera et al, 2010). To this 
end we used Tpp1lox/lox MEFs transduced with a lentiviral vector expressing Cre-shp53. 
Strikingly TRF1 levels were highly upregulated in Tpp1∆/∆ Cre-shp53 iPS cells when 
compared to the parental MEFs reaching similarly high levels to those of wild-type controls 
(Fig. 10A,B). These results clearly demonstrate that TRF1 upregulation at the induction of 
pluripotency is uncoupled from telomere elongation by telomerase. 
 
 
 
 
 
 
 
5.6 .  TRF1  EXPR ESSION  POS IT IVEL Y  C OR R EL ATES  W ITH  N AN OG 
PR OTE IN  EXPR ESSI ON  I N  IPS  C ELLS  
 To confirm the effects seen above, the experiment was repeated in a less automated 
manner. We studied the distribution of eGFP fluorescence in iPS cell clones of the different 
genotypes compared to the parental MEFs. In agreement with increased TRF1 expression 
associated with reprogramming, average eGFP-TRF1 fluorescence per nucleus was 
increased in eGFP-TRF1+/KI and eGFP-TRF1KI/KI iPS colonies compared to the parental 
MEFs (Fig. 11A&B). We also observed a significant increase in telomere length in all 
genotypes (on metaphase spreads), in agreement with telomere elongation during 
reprogramming (Fig. 11C&D) (Marion et al, 2009b). After normalization with wild-type eGFP-
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Figure 11. Increased eGFP-TRF1 expression after nuclear reprogramming. 
(A) Quantification of eGFP-TRF1 expression in indicated genotypes and cell types. Values indicate the 
average eGFP-TRF1 intensities per nucleus. (B). Blue, dapi; red, telomeres. MEF passage number =3, iPS 
passage number =6. (C) Analysis of a telomeric metaphase Q-FISH, measuring the telomere lengths of iPS 
cells and their corresponding MEFs. Differences in the telomeric length from MEF to iPS are similar in all 
three genotypes. Note, the increase in telomere length of eGFP-TRF1
+/KI
 and eGFP-TRF1
KI/KI
 iPS cells is 
underproportional to the average increase of eGFP-TRF1 expression in A&B. MEF passage number =3, iPS 
passage number =7. Statistical comparisons were done using two sided student t-test. (D) Representative 
pictures of the Q-FISH stained telomeres (red) in parental MEFs (left) and their corresponding iPS cell (right). 
 
background values, eGFP-TRF1KI/KI iPS colonies showed approximately double the amount 
of eGFP compared with the eGFP-TRF1+/KI iPS colonies (Fig. 11A&B). Intriguingly, we 
observed that eGFP-TRF1 fluorescence was not homogenously distributed and varied 
greatly  from nucleus to nucleus within the same iPS cell colony (Fig. 11B), suggesting that 
not all cells within an iPS cell colony are identical with respect to TRF1 expression . 
 
A B 
C D 
To understand the nature of the cell-to-cell eGFP-TRF1 heterogeneity in iPS 
colonies, we performed double immunofluorescence with OCT3/4 and Nanog antibodies. It 
has been previously reported that Nanog levels fluctuate and are not homogenous within ES 
and iPS cell cultures (Chambers et al, 2007; Villasante et al, 2011). Interestingly, we 
observed a positive correlation between Nanog and eGFP-TRF1 protein levels in eGFP-
TRF1+/KI and eGFP-TRF1KI/KI nuclei (Fig.12A). So that 50% of the iPS cells showing higher 
eGFP-TRF1 expression were also found to have higher Nanog expression than 50% of iPS 
cells with lower eGFP fluorescence (Fig. 12B&C).  Of note, a similar correlation was not 
observed in the case of OCT3/4 protein levels, which are also greatly upregulated in iPS 
colonies (Fig. 12A top right picture), further supporting a specific correlation between 
eGFP-TRF1 and Nanog protein levels. We confirmed this positive correlation between 
Nanog and eGFP-TRF1 by using flow cytometry analysis (Fig. 12D&E). In particular, we 
separated the cells into G1 (2n) and G2 (4n) populations and each cohort of the eGFP-TRF1 
expressing cells were further split into high and low Nanog expressing cells (ratio 1:1 see 
materials and methods). Concomitant with results obtained by immunofluorescence, we 
found increased eGFP-TRF1 expression in the Nanoghigh compared to Nanoglow cells both in 
heterozygous-KI and homozygous-KI iPS cells. The results obtained in heterozygous iPS 
cells were not significant, most likely due the low eGFP intensity which is difficult to detect by 
our instruments (Fig. 12D).  
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 Next, we addressed whether the positive correlation between eGFP-TRF1 and Nanog 
protein expression also occurred at the transcriptional level. To this end, we sorted live iPS 
cells (in G1 cell cycle state) into eGFP-TRF1 high and low expressing cells (40%:40%) and 
analyzed Nanog mRNA levels by RT-qPCR. First, we confirmed increased egfp-trf1 mRNA 
levels in heterozygous-KI and homozygous-KI iPS cells compared to wild-type iPS cells. 
EGFP-TRF1+/KI iPS cells showed approximately half the expression of egfp-trf1 if compared 
to eGFP-TRF1KI/KI iPS cells (Fig. 13A). According to expectations from immunostainings, 
eGFPhigh iPS cells showed more Nanog mRNA expression than eGFPlow cells in both 
heterozygous-KI and homozygous-KI clones (Fig. 13A). As control, Nanog mRNA was 
undetectable in wild-type MEFs and greatly elevated in the corresponding wild-type iPS cells 
(Fig. 13A). Of note, oct3/4 mRNA levels were similar in eGFPhigh and eGFPlow iPS cells in 
both heterozygous-KI and homozygous-KI clones. Interestingly, eGFP-TRF1low iPS cells that 
were grown for 3 days in gelatin coated dishes, were capable of re-establishing new iPS cell 
colonies with high expression of Nanog and eGFP-TRF1 (Fig. 13B), suggesting that high 
TRF1 levels can be re-established. 
 Also in agreement with eGFP-TRF1high pluripotent cells within iPS populations, we 
found elevated mtert mRNA levels in eGFPhigh iPS cells compared to eGFPlow iPS cells 
(Agarwal et al, 2010). Elevated mtert expression in the eGFPhigh iPS cells also correlated with 
longer telomeres in these cells compared to the eGFPlow iPS cells (Fig. 13C). In summary, 
both, the pluripotency markers, Nanog and mtert as well as telomere length are increased in 
the eGFPhigh iPS cells compared to eGFPlow iPS cells, suggesting that elevated egfp-trf1 
mRNA levels correlate with increased pluripotency.  
E 
Figure 12. Expression of eGFP-TRF1 in iPS cells is 
correlated with high levels of Nanog  
(A) Staining of iPS colonies (passage 6) with antibodies 
against Nanog and OCT3/4. Note that the eGFP-TRF1 
expression pattern is similar to that of Nanog. IPS passage 
number 6. (B+C) Analysis, showing the positive correlation 
between eGFP-TRF1 fluorescence intensity and Nanog 
expression levels in eGFP-TRF1
+/KI
 and eGFP-TRF1
KI/KI
 iPS 
cells (passage 6). Analysis depicts mean fluorescence 
intensities of eGFP-TRF1 and Nanog per nucleus. Statistical 
comparison in B was done using two sided student t-test and 
in C by linear regression analysis. (D&E) FACS analysis of 
wild-type, eGFP-TRF1
+/KI
 and eGFP-TRF1
KI/KI
 iPS cells 
(passage 7) grouped into Nanog
low
- and Nanog
high
 expressing 
cells (1:1). A positive correlation between eGFP-TRF1 
expression and Nanog-expression is found, similar to findings 
in parts B&C. Cell cycle states where separated by Hoechst 
staining. Statistical comparison was done using paired student 
t-test; us: unseparated 
E 
 Finally, we addressed whether the higher amounts of eGFP-TRF1 in pluripotent iPS 
cells were associated with the pluripotent state per se or could be related to increased 
division rates in these cells. To this end, we grew iPS cells on gelatine coated dishes in a 
medium containing fetal bovine serum (FBS), which is known to induce increased 
proliferation and loss of pluripotency (Bryja et al, 2006; Cheng et al, 2004). As expected, iPS 
cells grown under these conditions showed increased proliferation rates (Fig. 14A). On the 
other hand, eGFP-TRF1 expression was decreased in eGFP-TRF1KI/KI iPS cells after 4 days 
in FBS. The same trend was seen in the faster cycling eGFP-TRF1+/KI cells. The non 
significant decrease can be explained with the low eGFP-intensity in heterozygous cells that 
is close to the detection limit of the cytometer (Fig. 14B). The eGFP-TRF1 decrease was 
concomitant with a change in cell morphology towards a more differentiated state, known to 
A B 
Figure 13.  eGFP-TRF1 levels correspond with Nanog, mTERT and telomere length 
(A) mRNA levels of Nanog, Oct3/4, mTert, and eGFP-TRF1 in eGFP-TRF1
+/KI
 and eGFP-TRF1
KI/KI 
iPS 
clones (passage 7) after sorting for eGFP-TRF1 high and low levels (40%:40%) in the G1 cell cycle 
state. A positive correlation between eGFP-TRF1 fluorescence and mRNA levels of egfp-trf1, Nanog and 
mtert but not for oct3/4 was observed. Statistical analysis is done with paired t-tests. Error bars, SEM. 
(B) IPS cells sorted for high and low levels eGFP-TRF1
+/KI
 are both able to re-establish the pattern of 
known pluripotency markers such as Nanog (merge (red); bottom right hand picture, grey) and OCT3/4 
(top right hand picture). Also depicted are eGFP-TRF1 (merge (green); bottom left hand picture) and 
Dapi (merge (blue)). (C) Telomere length analysis by telomeric Q-FISH of eGFP-TRF1
+/KI 
and eGFP-
TRF1
KI/KI 
iPS-cells sorted according their eGFP-TRF1 content. Analyses of telomere-lengths show an 
increased telomere length in cells with high eGFP-TRF1 levels. Telomere length was calculated from the 
known telomere length of the “r” cell line (Experimantal Procedures). IPS passage number: 6-7. 
Statistical analysis is done with single sided paired t-tests. Error bars, SEM.  
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resemble the properties of the primary endoderm and the trophoectoblast (Fig. 14C) (Bryja 
et al, 2006; Cheng et al, 2004). These findings indicate that high eGFP-TRF1 expression in 
iPS cells is associated to pluripotency and lost upon differentiation of these cells, 
independent of the cell cycle frequency.  
 
5.7 .  EGFP-TRF1 H I G H  C ELLS  R EPR ESEN T A S U B POPU L AT I ON  OF  I PS  
C ELLS  W ITH  H I GHER  PL U R IP OTEN C Y POTEN T I AL  
 To further determine the properties of eGFPhigh iPS cells compared to eGFPlow iPS 
cells, we tested their respective abilities to form chimeras and teratomas, an indication of 
their pluripotency potential. To this end, we sorted eGFPhigh and eGFPlow iPS (eGFP-
TRF1+/KI) cells in the G1 cell cycle state (avoiding possible differences in telomere numbers 
and therefore eGFP-TRF1 levels; see in experimental procedures). For teratoma formation, 
we injected the sorted iPS cells with the highest and lowest (40%:40%) eGFP-TRF1 
fluorescence into the flanks of nude mice. Strikingly, only the eGFP-TRF1high sorted iPS cells 
were capable of forming teratomas and no teratomas were obtained with the eGFP-TRF1low 
sorted iPS (Fig. 15A&B). Furthermore, teratomas obtained from eGFP-TRF1high sorted iPS 
cells showed all three germ layers indicating that they are pluripotent (Fig. 15C). Similar to 
the iPS colonies in vitro, expression of eGFP-TRF1 highly correlated with the expression of 
Nanog in teratoma sections, indicating that the undifferentiated regions expressed higher 
amounts of eGFP-TRF1 compared to more differentiated areas (Fig. 15D&E). This confirms 
A B C 
Figure 14. Expression level of eGFP-TRF1 does not correlate with the replication frequency. 
(A) eGFP-TRF1
+/KI
 (+/KI) and eGFP-TRF1
KI/KI
 (KI/KI)
 
iPS clones grown on gelatine for four days in medium 
with knockout serum replacement (KSR) or in medium with fetal bovine serum (FBS). Cells cultured in FBS 
medium show lower eGFP intensities as measured on trypsinised and alive cells by flow cytometry. Statistical 
analysis is done on median values with single sided paired t-tests. Error bars, SEM. (B) IPS cells grown in 
FBS medium show significantly increased proliferation rates compared to the same clones grown in KSR 
medium. Cell count was done with standard Neubauer cytometry. Statistical analysis is done with the two way 
ANOVA test. Error bars, SEM. (C) Representative images of eGFP-TRF1
+/KI
- and eGFP-TRF1
KI/KI
-clones at 
day 4 of FBS addition. In the left column we see the clones grown in KSR and on the right, the same clones 
grown in medium containing FBS. The cells on the right hand side show a clear pattern of differentiation. 
 
that TRF1 expression is an indicator of the degree of differentiation within the tumor. Wild-
type iPS cells were not able to form teratomas when injected into nude mice. This, might be 
due to the limited amount of cells (1.5x106 cells per injection) that can be sorted and used for 
this experiment as well as the harsh sorting environment. Further, it points to a positive 
selection for pluripotent iPS cells of the eGFP-TRF1+/KI genotype. Cells that are administered 
without sorting (2x106 cells per injection) are able to form teratomas and differentiate into all 
the 3 germ layers. However, they have a later onset and show growth retardation. 
 
 
 
 
 
 
Figure 15. High expression of eGFP-TRF1 marks pluripotent iPS cells 
(A) Teratoma formation by iPS cells (passage 4) sorted for high and low eGFP-TRF1 expression in the G1 
phase of the cell cycle (red) and by non-sorted iPS cells (grey). From the sorted cells, only eGFP-TRF1
+/KI
 high 
iPS cells formed teratomas. Of the unsorted cells all the different genotypes formed teratomas with a later 
onset. The earlier teratoma onset of the sorted eGFP-TRF1
high
 iPS cells compared to the unsorted cells 
indicates that high eGFP-TRF1 expression marks a subpopulation of more pluripotent stem cells within the bulk 
iPS cells. Depicted are the means of tumor volume per genotype and day after injection. (B) Representative 
images of nude mice injected with unsorted wild-type and eGFP-TRF1
KI/KI
 iPS cells (left picture) and sorted for 
high and low eGFP-TRF1 in eGFP-TRF
+/KI 
iPS cells (right). (C) Representative image of an eGFP-TRF1
+/KI
 
teratoma stained for H&E showing all the three germ layers (endoderm: end; mesoderm: mes; ectoderm: ect). 
(D) Representative picture of a teratoma induced by eGFP-TRF1
+/KI
 iPS cells. The OCT section was stained for 
Nanog (red). In the depiction we can see, that there are regions that did not differentiate or dedifferentiated 
again (Nanog positive cells). In those regions, in opposite to the more differentiated sites, we can detect a 
highly increased amount of eGFP-TRF1 at the telomeres. (E) Heat maps of the indicated region in D. The left 
heat map shows a colorcoded picture in which the cells with high Nanog expression have warmer colors and 
vice versa. A very similar pattern is seen in the eGFP-TRF1-heat map done in the same way. (F) Statistical 
correlation analysis of the teratoma cells for the expression eGFP-TRF1 and Nanog. We see a significant 
correlation for eGFP-TRF1 expression and Nanog. Statistical analysis is done for the linear regression. 
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Similar results were obtained using iPSc’s, sorted as described above, for morulae 
aggregation in a chimera forming assay. EGFPlow iPS cells sorted from eGFP-TRF1+/KI clones 
did not contribute to chimera formation whereas the high eGFP-TRF1 containing iPS cells 
contributed to chimeric mice represented in the high percentages of chimerism  (Fig. 16 
A&B).  
 
 
 Together, these results support the notion that TRF1 expression levels are indicative 
of the level of pluripotency of iPS cells. Thus, the higher the expression levels of TRF1, the 
higher the pluripotency potential. 
A 
B 
Figure 16. High expression of eGFP-TRF1 
marks pluripotent iPS cells 
(A&B) Numbers and graphical depiction of the 
chimera formation assay with iPS cells sorted for 
low and high eGFP-TRF1 expression. Note that 
only the sorted eGFP-TRF1
high
 iPS cells from the 
eGFP-TRF1
+/KI
 genotype contributed to chimeras. 
Sorting of the wild-type iPS cells was based on the 
background levels treat them the same as the 
eGFP-TRF1 cells. 
 
 
 
5.8 .  TRF1  IS  ESSEN TIAL  F OR  R EP R O GRAM M IN G  
Having seen higher expression levels of TRF1 in undifferentiated cells, we set out to 
determine whether TRF1 itself behaved like other pluripotency genes and was essential for 
the reprogramming of MEFs into iPS cells. To this end, we reprogrammed MEFs deficient for 
TRF1 and simultaneously abrogated p53. The deletion of p53 in TRF1∆/∆; p53-/--Cre MEFs, 
was able to rescue proliferative defects associated with TRF1 deficiency and facilitated 
reprogramming of cells with severe telomeric damage (Marion et al, 2009a; Martinez et al, 
2009). Strikingly, we repeatedly failed to obtain any iPS cell colonies in the TRF1∆/∆; p53-/--
Cre cultures (Fig. 17A). All colonies formed showed no TRF1 excision and contained the 
TRF1lox/lox; p53-/--Cre (Fig. 17B). This indicates that TRF1 deficiency completely blocks 
reprogramming, even in the absence of p53. In agreement with an essential role for TRF1 in 
reprogramming, TRF1 deficiency prevented some of the key events associated with the 
process of reprogramming. One of them is the appearance of ssea-1 mRNA expressing 
clones in the first week post reprogramming (Fig. 17C) (Stadtfeld et al, 2008a). Another key 
event that was impaired in TRF1-deficient cultures is the induction of high transcription levels 
of the pluripotency genes Nanog and oct3/4 at the time of appearance of the first iPS clones  
at day 14 post-infection (Fig. 17D).  
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5.9 .  IN D U C TI ON  OF  AP OPT OS I S ,  C H R OM OS OM AL  AB ER R ATI ON S  AN D  
DDR  AC T IV AT I ON  I N  TRF1-D EFIC IEN T  IPS  C ELLS  
Next, we wondered whether TRF1 is just a marker of pluripotency or if it is important for 
the maintenance of pluripotency in iPS cells. To this end, we generated TRF1-null iPS cells 
using primary MEFs carrying a conditional loxP-flanked TRF1 and an inducible Cre-ERT2 
recombinase (RERTn) allele. After reprogramming of TRF1lox/lox; RERTn+/ERT and TRF1+/+; 
RERTn+/ERT MEFs, the resultant iPS cells were cultured in the presence of 4-
hydroxytamoxifen (4-OHT) to obtain TRF1∆/∆ and TRF1+/+ iPS cells. It has been previously 
described that TRF1 deficiency in MEFs induces telomere uncapping, telomere fragility and a 
rapid induction of cell-cycle arrest and senescence, mediated by the p53 and pRb pathway 
activation (Martinez et al, 2009). As iPS cells are very sensitive to DNA damage, we checked 
whether TRF1∆/∆ iPS cells undergo apoptosis. At day 6 of 4-OHT treatment we observed an 
increase in apoptosis in TRF1/; RERTn+/ERTOHT iPS cells compared to the TRF1+/+; 
RERTn+/ERTOHT iPS cells, while there were no significant differences in control-treated iPS 
cells (Fig. 18A&B). To address whether TRF1 deficiency causes telomeric aberrations in iPS 
cells, we performed a telomeric Q-FISH on metaphases (Experimental Procedures). As 
expected, TRF1/; RERTn+/ERTOHT iPS cells showed higher levels of MTS, sister-chromatid 
and chromosome fusions at day 3 and day 6 after 4-OHT treatment (Fig. 18C), suggesting 
increased telomere fragility and telomere uncapping, due to TRF1 abrogation. The DDR 
activation was analyzed by co-staining of γH2AX and TRF1 in iPS cells at day 3 of 4-OHT 
treatment. We observed a significant increase in the percentage of γH2AX positive cells (Fig. 
18D&E) in TRF1/; RERTn+/ERTOHT cells with low levels of TRF1 compared to TRF1+/+; 
RERTn+/ERTOHT and TRF1/; RERTn+/ERTOHT cells with incomplete TRF1 excision was 
detected. These findings are in agreement with the results from TRF1-null MEFs. Finally, we 
confirmed TRF1 abrogation in TRF1/; RERTn+/ERTOHT iPS cells by qRT-PCR (Fig. 18F) at 
Figure 17.  Very high TRF1 levels during reprogramming are essential for the generation of iPS 
cell clones. 
(A) Relative reprogramming efficiencies of the indicated cells. Note that the only iPSs colonies obtained 
from the TRF1
lox/lox
-Cre MEFs came from cells without TRF1 excision. Statistical comparisons were done 
using two sided student t-test. Error bars, SEM. n= independent experiments. (B) Reprogramming plates 
stained with alkaline phosphatase. The number of parental MEFs used is indicated. Analysis of TRF1 
excision in iPS colonies obtained from TRF1
lox/lox
 p53
-/-
 -Cre MEFs by PCR. Note that all the clones keep 
the TRF1
lox/lox
 locus. (C) Kinetics of mRNA expression of ssea-1 pluripotency marker during 
reprogramming, as measured by flow cytometry. Non-reprogrammed MEFs are shown as negative 
control. Error bars, SEM. n= experiments from independent MEFs. (D) mRNA levels of oct3/4, Nanog 
and trf1 at days 9, 11 and 14 of reprogramming, before appearance of iPS colonies. The mRNA levels 
are measured by qRT-PCR relative to GAPDH mRNA levels. Statistical comparisons were done using 
two sided student t-test. Error bars, SEM. n= independent MEFs. 
 
 
 
day 3 and 6 of 4-OHT treatment. These results confirm an important role of TRF1 in IPS cell 
maintenance. 
Figure 18. Conditional TRF1 ablation in iPS cells leads to apoptosis, chromosomal aberrations and DDR 
activation  
(A) Apoptosis was determined by Annexin staining on control treated iPS cells and iPS cells at day 3 and 6 of 4-
hydroxytamoxifen treatment. n= number of iPS clones analyzed. Statistical comparisons were done using two 
sided student t-test. Error bars, SEM. (B) Representative FACS profiles at day 6 of 4-hydroxytamoxifen 
treatment. (C) Frequency of aberrations in metaphase spreads of the indicated genotypes and conditions. n= 
number of metaphases from a total of two iPS clones per genotype. Statistical comparisons were done using 
two sided student t-test. Error bars, SEM. (D) Percentage of γH2AX positive cells in non-treated (Ctrl) and 
treated with 4-hydroxytamoxifen (Day 3) iPS cells. n= number of iPS clones used for the analysis. The total 
number of cells analyzed per genotype is shown. Statistical comparisons were done using two sided student t-
test. Error bars, SEM. (E) Representative images of TRF1 and γH2AX immunofluorescence co-staining. (F) 
mRNA levels of TRF1 decrease with time of 4-OHT treatment as it is depicted for day 3 and day 6. In the left 
panel we see control treated cell at day 3 where no difference in the TRF1 mRNA levels was detected. 
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  Knowing that TRF1 deficiency completely blocks reprogramming in a p53-null 
background and, that TRF1 is essential for iPS cell maintenance (Fig. 17A), we set to 
confirm this essential role for TRF1 in reprogramming by knocking-down TRF1 expression 
during the reprogramming process. To this end, p53-/- MEFs were reprogrammed using a 
cocktail of the three reprogramming factors (lentiviral Oct4, Klf4 and Sox2) and a lentiviral 
vector expressing either TRF1 shRNA or a scramble shRNA as a control. Reprogramming 
efficiency was calculated as the number of iPS cell colonies obtained relative to the total 
number of cells initially infected (infection efficiency was measured in quintuple infections 
with the three factors, GFP plus the lentiviral vector, and analyzed by flow cytometry to 
detect the proportion of GFP-positive cells). We observed that a reduced expression of TRF1 
during reprogramming strongly decreases the reprogramming capacity of the cells (Fig. 19A) 
in agreement with an essential role for TRF1 in reprogramming. As the abrogation of TRF1 
induces a strong DDR and increases the presence of chromosome termini with MTS, 
telomere uncapping (presence of DSB signalling) and SCF (Martinez et al, 2009) we next 
studied whether knocking-down TRF1 expression during the reprogramming process induces 
the appearance of the above mentioned pheotypes. First, we measured the expression of 
γH2AX that has been shown to mark the presence of DNA double-strand breaks, including 
those associated with critically short or dysfunctional telomeres. Eight days after the 
reprogramming initiation with the reprogramming cocktail and the scramble or TRF1 
shRNAs, colonies were not yet detectable. The readout on the other hand already showed a 
significant increase of the nuclear intensity of γH2AX in cells with reduced levels of TRF1 
(Fig. 19B). This suggests that this damage could, at least in part, be responsible for the 
deficient reprogramming capacity of these cells. Next, we determined the frequency of MTS 
at day 10 post infection, when iPS colonies were not yet present, and at day 17, when iPS 
colonies were clearly detectable. We observed that infection with the reprogramming factors 
did not increase the frequency of MTS at day 10 p.i.  , neither in cells deficient for TRF1 nor 
in cells with normal levels of TRF1 (Fig. 19C, left). However, at day 17 p.i.  a significant 
increase in MTS was detected in  cells deficient for TRF1 when compared with cells with 
normal levels of TRF1 (Fig. 19C, right), suggesting that accumulation of MTS may be a 
consequence of the multiple cell divisions required to generate an iPS colony. 
Together, these findings indicate that TRF1 is essential both for the induction and 
maintenance of pluripotency in iPS cells. 
      
 
 
Figure 19. Down-regulation of TRF1 during reprogramming significantly impairs reprogramming 
and induces DNA damage and telomere aberrations 
(A) Left, quantification of relative reprogramming efficiency of primary p53
-/- 
MEF infected with three 
reprogramming factors (retroviral) plus scramble shRNA or TRF1 shRNA (lentiviral). Efficiency of iPS 
generation was calculated as the number of alkaline phosphatase- positive colonies and normalized to 
retroviral infection efficiency as determined by GFP fluorescence. Note that down-regulation of TRF1 
expression strongly reduces reprogramming efficiency. Right, representative images of the 
reprogramming plates. (B) Quantification of TRF1 and γH2AX immunofluorescence after infection with 
the indicated viral cocktails (day 8 p.i). Note that down-regulation of TRF1 expression significantly 
increases the presence of γH2AX in cells infected with the reprogramming factors. Indicated statistics 
was performed using a Student’s t-test. Error bars, SEM. n= number of cells analyzed. (C) Frequency of 
multitelomeric signals in cells 10 days (no presence of iPS colonies) or 17 days (presence of iPS cells) 
after infection with the indicated viral cocktails. Note that down-regulation of TRF1 expression increases 
the presence of multitelomeric signals in the resulting iPS cells at day 17 p.i. The number of metaphases 
analyzed in each case is indicated. Statistical comparisons were done using two sided student t-test. 
Error bars, SEM. 
 
 
 
A 
B 
C 
  
R
e
s
u
lt
s
 
5.10.  TRF1  EXPR ESSION  LEVELS AR E  M ODU L ATED  B Y TH E  
OC T3/4  TR AN SCR IPT I ON  F AC TOR  B Y  D IR EC TLY  B IN D IN G  T O 
TRF1  PR OM OTER  I N  PLU R IP OT EN T C ELLS  
The results described above indicate an unprecedented role for TRF1 linked to 
induction and maintenance of pluripotency in iPS cells, which is independent of telomere 
elongation by telomerase. Interestingly, this is not restricted to the in vitro generated iPS 
cells, as TRF1 levels are also upregulated during the in vitro establishment of mouse 
embryonic stem (ES) cells coincidental with upregulation of known pluripotency genes, such 
as Sox2 or Oct3/4 (Varela et al, 2011). Thus, we next set out to address the mechanism by 
which TRF1 is upregulated associated to the induction of pluripotency. Recent ChIP-
sequencing experiments showed that the pluripotency factor OCT3/4 can bind to TRF1 
promoter regions (Loh et al, 2006), suggesting that OCT3/4 could be responsible for TRF1 
upregulation during reprogramming. To directly test this, we transduced wild-type MEFs with 
each of the “Yamanaka factors” (namely Oct3/4, Sox2 and Klf4) using retroviral vectors 
(Experimental Procedures). Three days after infection a significant increase in TRF1 levels 
was detected only in Oct3/4-transduced MEFs, even in the absence of reprogramming. 
Sox2- or Klf4-transduced MEFs did not show such increased TRF1 levels when compared to 
wild-type MEFs (Fig. 20). Of note, even though OCT3/4 was sufficient to induce TRF1 in 
MEFs, TRF1 levels in established iPS were still significantly higher (Fig. 20). These results 
suggest that OCT3/4 is sufficient to induce TRF1 upregulation during the reprogramming 
process, but additional factors are required for full TRF1 induction in iPS cells.  
Figure 20. The transcription factor OCT3/4 modulates TRF1 
expression in pluripotent cells . 
TRF1 expression levels in MEFs transduced with either Oct3/4, 
Sox2 or Klf4, as estimated by qRT-PCR. Depicted is mRNA fold 
increase relative to TRF1 levels in wild-type MEFs three days 
after transduction with the indicated retroviral vectors. Note that 
Oct3/4/4 is the only factor that is able to increase TRF1 levels in 
the absence of cellular reprogramming. Non-transduced MEFs 
and wild-type iPS cells are included for reference. n=number of 
independent MEF clones used per condition. Bars represent the 
average of all the independent experiments performed. 
Statistical comparisons were done using two sided student t-
test. Error bars, SEM. 
 
  
 
  OCT3/4 is one of the core components of the “Yamanaka’s Reprograming Coctail” 
(Niwa, 2007; Takahashi et al, 2007), and very few reports have shown feasible alternatives 
for substituting OCT3/4 in the reprogramming of somatic cells (Heng et al, 2010; Redmer et 
al, 2011). We have already demonstrated that eGFP-TRF1 strongly co-localizes with Nanog 
by immunofluorescence in eGFP-TRF1+/KI iPS cells (Fig. 12A-E). Moreover, we have shown 
that forced OCT3/4 expression is sufficient to induce TRF1 upregulation in differentiated cells 
(Fig. 20). Given its importance together with Nanog in the maintenance of stem cell identity 
and self-renewal, together with the essential nature of TRF1 in pluripotent cells, we wanted 
to test whether OCT3/4 or Nanog are able to directly bind the TRF1 promoter in mouse 
pluripotent cells. This was addressed with ChIP-qRT-PCR experiments in ES- and iPS cells 
(Fig. 21A-C). We immunoprecipitated chromatin bound OCT3/4 and Nanog and analyzed 
either OCT3/4 promoter (OCT3/4-Pr), Nanog promoter (Nanog-Pr), TRF1 promoter (TRF1-
Pr) or an unrelated control region upstream of TRF1 promoter (Ctrl Region) (Fig. 21C). In ES 
cells, we were able to detect significant binding of OCT3/4 protein to both, OCT3/4-Pr, 
Nanog-Pr and TRF1-Pr. We also detected Nanog binding to its own promoter and that of 
OCT3/4; however, TRF1-Pr was not detected upon Nanog ChIP-qRT-PCR (Fig. 21A). To 
demonstrate that OCT3/4 binding to TRF1 promoter was not an exclusive feature of mouse 
ES cells, we performed the same ChIP-qRT-PCR experiments in iPS cells, confirming our 
previous observations (Fig. 21B). These results demonstrate that OCT3/4 that itself is 
depending on bona-fide pluripotency markers such as Nanog or SOX2, can directly regulate 
TRF1 levels which supports the hypothesis that TRF1 is an essential protein during the 
acquisition of pluripotency. Nanog has been shown to bind to the TRF1 locus, but functional 
assays implicating its role in TRF1 regulation remain to be verified (Loh et al, 2006). 
A B 
  
R
e
s
u
lt
s
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. The transcription factor Oct3/4 modulates TRF1 expression in pluripotent cells by 
directly binding to TRF1 promoter. 
DNA levels, as measured by qRT-PCR after Chromatin Immunoprecipitation (ChIP) in ES cells (A) or 
iPS cells (B). The amount of DNA in each ChIP was normalized to its corresponding input DNA levels 
(total genomic DNA not subjected to immunoprecipitation). The antibodies used are indicated under 
each bar of the graph, the regions amplified by qRT-PCR are indicated on top of the panels (Ctrl Region, 
control region; Oct3/4 Pr, Oct3/4 promoter; TRF1 Pr, Terf1 promoter; and Nanog Pr, Nanog promoter). 
Note that OCT3/4 binds to Trf1, Nanog and Oct3/4 promoters, while Nanog does only bind to Nanog and 
Oct3/4 promoters but not that of TRF1. n=number of independent immunoprecipitations performed. Bars 
represent the mean of at least three experiments. Statistical comparisons were done using two sided 
student t-test. Error bars, SEM. (C) Schematic representation of the genomic regions and primer pairs 
used for the ChIP-qRT-PCR analysis described in (A) and (C). 
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5.11.  EGFP-TRF1  EXPR ESSI ON  AS  A M AR K ER  F OR  AD U LT  
STEM  C ELL  C OM PAR TM EN T S  
5 . 1 1 . 1 .  T A I L  S K I N  H A I R  F O L L I C L E  
Having established new roles of TRF1 in pluripotent iPS- and ES cells; the TRF1 
expression pattern in tissues and in their corresponding stem cells became of great interest. 
Previous work in our lab described that cells harbouring the longest telomeres within a tissue 
are enriched in the known stem cell compartments, while cells showing shorter telomeres are 
normally located in the differentiated compartments (Flores et al, 2008). In the case of the 
small intestine stem cell niche, cells with the longest telomeres were enriched at the +4 to +7 
positions within the crypt as well as in the TA area, while cells with the shortest telomeres 
where more abundant in the 0 to +3 and villi regions (Flores et al, 2008). In the case of the 
skin, cells with the longest telomeres where enriched at a broad defined hair bulge region 
and telomere length progressively decreased via TA compartments with the shortest 
telomeres at the interfollicular epidermis (Flores et al., 2008).  Here, we set to address 
whether TRF1 expression showed a similar distribution to that of telomere length in both 
small intestine and skin adult stem cell compartments. To this end, we followed eGFP 
expression in both tail skin and small intestine from eGFP-TRF1+/KI mice.  
In tail skin, we found maximum eGFP-TRF1 fluorescence at the known stem cell 
compartments of the epidermis (EP), sebaceous gland (SG) and hair follicle (FOL) (Ito et al, 
2005; Jensen et al, 2009; Snippert et al; Woo & Oro, 2011), and eGFP fluorescence was 
minimal in the interfollicular epidermis where differentiated cells are present (Fig. 22A-C).   
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Figure 23. High expression of eGFP-TRF1 marks pluripotent iPS cells 
(A) Representative Image of a telogen tail-skin hair follicle stained for Cytokeratin15 (CK15) (top picture). In 
the middle picture eGFP-TRF1 fluorescence is visible. The close-up, as marked in the third row merge picture, 
is depicted on the right of each picture showing CK15 positive and negative cells. (B) Quantification of the 
average background (bg) corrected eGFP-TRF1 fluorescence in CK15 positive and negative tail-skin follicle 
cells. We can see a significant increase from CK15 negative to positive cells Statistical analysis is done using 
two sided t-tests ; Error: SEM. 
 
 
To confirm an enrichment of eGFP-TRF1 in the stem cell compartment, we next 
studied eGFP-TRF1 fluorescence in CK15-positive cells, a bona fide marker of hair follicle 
stem cells (Liu et al, 2003).  As shown in Fig. 23A&B, CK15-positive cells in the tail skin 
were enriched at the hair bulge, epidermal- and sebaceous gland stem cells and showed 
higher eGFP fluorescence compared to CK15-negative cells.  This result is in line with 
previous findings from our group showing that the longest telomeres are enriched at the 
CK15-positive cells (Flores et al, 2008). Interestingly, we noticed that changes in the 
expression of eGFP-TRF1 between the different skin compartments were much more 
pronounced than changes in telomere length. In particular, while telomere length decreased 
from the hair stem cells to interfollicular epidermis by 30% (Flores et al, 2008), we observed 
a drop in eGFP-TRF1 fluorescence of around 70% for the same compartments (Fig. 22A-C). 
This finding suggest that TRF1 levels, also in the adult stem cell compartments, are 
uncoupled from the telomere length, similar to the findings in in-vitro conditions, where iPS 
cells show a massive, disproportional increase in TRF1 levels compared to their parental 
embryonic fibroblasts. 
 A B 
Figure 22. eGFP-TRF1 expression is maximal in adult stem cell compartments of the skin  
(A) Representative image of eGFP-TRF1 fluorescence in the indicated compartments of tail-skin follicles 
in the telogen state. EGFP-TRF1 intensity decreases from the putative stem cell niches towards all the 
more differentiated compartments (interfollicular skin). (B&C) Quantification of eGFP-TRF1 fluorescence 
in the Epidermal- (ED), sebaceous gland (SG)-, follicular (FOL) stem cells, bulb, infundibulum (inf.) and 
interfollicular areas (int. area) of the tail-skin follicles. There is a significant decrease of the average 
(avg.) background (bg) corrected eGFP-TRF1 fluorescence when going from the putative stem cell 
niches towards the more differentiated compartments. Statistical analysis is done by two sided t-tests. 
Error bars, SEM. 
 
5 . 1 1 . 2 .   I N T E S T I N A L  S T E M  C E L L S  
 Next, the small intestine stem cell compartments were addressed. In this case, the 
highest eGFP fluorescence was found in the area above the region containing paneth cells 
(position 0 to +3), namely from cellular position +4 to +7 and the lowest expression at the villi 
(Fig. 24A-E), also in agreement with previous findings for long telomeres (Flores et al, 2008). 
Similar to our observations in vitro and tail skin tissue samples, we detected a much more 
abrupt drop in eGFP fluorescence than in telomere length when comparing the less 
differentiated to the more differentiated compartments. In particular, eGFP-TRF1 expression 
was lowered from positions +4 to +7 to villi cells by 94% (Fig. 24D), while telomeres in the 
same compartments shortened by only 14% (Flores et al, 2008). We confirmed these 
findings also for endogenous TRF1 expression by performing immunofluorescence with anti-
TRF1 antibody (Fig. 24C&E). In this case, we observed a decrease of TRF1 expression of 
80% from positions +4 to +7 to villi cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
  
R
e
s
u
lt
s
 
 
 
 
  
 There is recent evidence to suggest that small intestine stem cells are located at the 
bottom of the crypts at position 0 to +3 and that they can be identified by high Lgr5 
expression, whereas neighbouring paneth cells are more differentiated and do not express 
Lgr5 (Schepers et al, 2011). In order to address whether Lgr5+ cells also show high TRF1 
expression compared to the Lgr5-negative paneth cells, we determined TRF1 fluorescence 
in Lgr5-eGFP reporter mice (Barker et al, 2007).  
 We readily noticed that TRF1 expression was not homogeneous at the bottom of the 
crypt, with the eGFP-positive cells (Lgr5+) showing the highest TRF1 expression, comparable 
to that of +4 to +7 cells (Fig. 25A&B). Interestingly, this marked difference in TRF1 
expression between the Lgr5+ cells and the rest of the 0 to+3 positioned cells was not 
observed in the case of telomere length. This further supports the hypothesis that TRF1 
expression is uncoupled from telomere length, also in the adult stem cell compartments (Fig. 
25A-D). The fact that we did not see significant changes in telomere length between the 
Lgr5+ and Lgr5-negative cells, both having significantly shorter telomeres than cells at the +4 
to +7 position, is in agreement with our previous findings (Flores et al, 2008) but in contrast 
with recent findings by other authors (Sato et al, 2010).  Our results would suggest that, in 
terms of telomere length, the paneth-cell interspersing Lgr5-positive cells are not those with 
the longest telomeres and, presumably, the cell population with longer telomeres may 
Figure 24. eGFP-TRF1 expression is maximal in adult stem cell compartments of the small 
intestine 
(A) Representative image of eGFP-TRF1 fluorescence (left), Merge image (middle) and a total TRF1 
staining (right) in small intestine-crypt/villi. The highest eGFP-TRF1 and TRF1 fluorescence is located in 
the positions +4-+7 of the intestinal crypt and decreases towards the more differentiated cell types in the 
crypt/villi. (B) Quantification of the average background (bg) corrected eGFP-TRF1 fluorescence in the 
indicated compartments of the intestinal crypt/villi. We see the highest eGFP-TRF1 expression in cells 
located at positions +4 to +7. It decreases towards the more differentiated regions. Indicated is the 
background corrected mean green value per nucleus. Statistical analysis is done using two sided t-tests. 
(C) Quantification of the eGFP-TRF1 and the total TRF1 in the different compartments of the intestinal 
crypt/villi. We see a significant decrease of eGFP-TRF1 expression in nuclei from the putative stem cell 
niche (position +4 to +5) towards the more differentiated regions. Indicated is the background corrected 
mean TRF1 value per nucleus. Error, SEM; statistical comparisons were done using two sided student t-
test. (D&E) Quantification of the eGFP-TRF1 and total TRF1 expression, analyzed per intestinal crypt of 
the different areas. Error bars, SEM; statistical comparisons were done using two sided student t-test. 
 
 
 
 
D E 
contain additional stem cells, in line with recent findings that Lgr5+ cells are dispensable for 
maintenance of intestine homeostasis (Tian et al, 2011) and the idea of fast and slow cycling 
stem cells in the small intestine. 
 
 
Figure 24. High expression of eGFP-TRF1 marks pluripotent iPS cells 
(A) Left panel: different cell types of the intestinal crypt/villi using the indicated color-code. Right panels: 
Lgr5-eGFP fluorescence (green; close-up at the bottom), TRF1 fluorescence (red; middle close-up), and 
merged TRF1 and Lgr5-eGFP fluorescence (close-up at the top) in small intestine crypt/villi of a 
heterozygous Lgr5-eGFP mouse. (B) Quantification of average TRF1 fluorescence per nucleus in 
arbitrary units (a.u) in the indicated compartments. The highest expression of TRF1 is seen at the +4 to 
+7-cells followed by the Lgr5-GFP
+
 and TA cells. Note that Lgr5-GFP
+
-cells in the crypt express much 
higher levels of TRF1 than the neighboring Paneth cells. From +8 position to the villi, cells express less 
TRF1 coincidental with increased differentiation of those cells. Calculations made by two tailed, paired 
(within crypts) t-test. Error: SEM. (C) Representative picture of an anti Lgr5-GFP GFP-telomere immuno-
FISH. Bottom panel: Lgr5-GFP fluorescence marks the Lgr5+-cells. Middle panel: Tel-PNA-Cy3 probe 
shows telomeres fluorescence.  Top panel: merged picture shows similar telomere intensity in the Lg5+ 
and Lgr5- cells in the 0 to +3 compartment. (D) Remarkably, in the 0 to +3 region the telomeres of Lgr5-
GFP
+
 cells compared to the +4 to +7 position are severely shortened. We do not see any statistical 
difference in telomere length between paneth (Lgr5-GFP
-
) cells and Lgr5-GFP
+
 cells in the 0 to +3 region 
(J). Calculations made by two tailed paired (within crypts) t-test. Error: SEM. 
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 Together, these findings underline a previously unnoticed enrichment of TRF1 
expression in the adult stem cell compartments of mouse tissues. Furthermore, the fact that 
TRF1 expression drops more acutely than telomere length when going from stem cell 
compartments to the most differentiated compartments within tissues, underlines a role for 
TRF1 that is independent of telomere length regulation. 
5.12.  CON D IT I ON AL  AB L AT I ON  OF  TRF1  IN  IN TEST IN E  LEAD S 
T O SEVER E IN TEST IN AL  ATR OPH Y  
 
To address whether TRF1 is essential for tissue homeostasis, we conditionally 
knocked out TRF1 in the small intestine by crossing the TRF1lox/lox mouse model previously 
generated in our laboratory (Martinez et al, 2009) with a Villin-CreERT2 expressing mouse 
(el Marjou et al, 2004), thus targeting TRF1 deletion to villin expressing tissues. In this 
mouse model, the Cre-ERT2 is homogeneously expressed along the crypt-villus axis in both 
differentiated and undifferentiated cells (Janssen et al, 2002; Pinto et al, 1999; Robine et al, 
1997). By PCR, we detected specific excision of TRF1 in the Villin-expressing tissues such 
as the small intestine and colon but not the spleen (negative control) (Fig. 26A). This 
resulted in a marked decrease in TRF1 protein expression as shown in the heatmaps of 
figure 26B. In particular, while control TRF1+/+;Villin-CreERT2+/T mice show a normal small 
intestine morphology and normal TRF1 expression enriched at the crypts (particularly at the 
+4 to +7 position) (Fig. 26B, top panel; Fig. 28A), TRF1lox/lox;Villin-CreERT2+/T mice show a 
dramatic decrease of TRF1 expression in most intestinal cells (Fig. 26B, bottom panel; Fig. 
28A). This was concomitant with severe weight loss in some individuals (Fig. 26C) and 
aberrant intestinal morphology going from moderate lesions to severe lesions where the 
normal structure of the cript/villi was lost (Fig. 27A, left panel). In the moderate lesions, we 
observed a shortening of the villis and a diffuse inflammatory infiltration with lymphoid cells. 
Interestingly, almost all crypts that were moderately lesioned contained at least one cell at 
position +4 to +7 with residual TRF1 expression. (Fig. 27A, left-middle panels). Moderate 
lesions additionally led to a lower density of crypts/villi (Fig. 27B). In the severe lesions the 
morphology of the intestine was lost, showing severely atrophic microvillis, a higher amount 
of lymphoid infiltrates and a lamina propia in the duodenum without Brunners glands  
concomitant with a complete loss of TRF1 expression (Fig. 27A, left-bottom panels). This 
was coincidental with an increased abundance of apoptotic cells and cells with big-, 
endoreduplicated nuclei (Fig. 27A, right panel; quantification in Fig. 27C&D). The highest 
amount of apoptotic and endoreduplicated cells was found at the stem cell region from +4 to 
+ 7 positions (Fig.  27C&D). Increased apoptosis was also confirmed by caspase3-positive 
staining (data not shown).  
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Figure  26. Conditional TRF1 deletion in the small intestine leads to severe degeneration of villi 
and crypts coincidental with increased DNA damage, apoptosis and replication problems at the 
stem cell areas. 
(A) PCR confirmation of TRF1 excision in the villin-expressing tissues of the colon and the small 
intestine but not in the spleen. The upper TRF1
lox/lox 
band might correspond to lymphocytes present in 
the intestine. (B) Heat maps indicating the amount of TRF1 per nucleus in the intestine (warmer colors 
stand for higher amounts of TRF1). The small intestine areas showing chronic lesions are completely 
ablated for TRF1 expression (bottom). (C) Bodyweight of TRF1
+/+
; Villin-CreERT2
+/T
 (black) and 
TRF1
lox/lox
; Villin-CreERT2
+/T
 (red)
 
mice during the treatment with 4-OHT. Two TRF1
lox/lox
; Villin-
CreERT2
+/T
 mice lost weight rapidly (indicated by *) and had to be sacrificed. 
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 Figure 27. Conditional TRF1 deletion in the small intestine leads to severe degeneration of villi 
and crypts coincicental with increased DNA damage, apoptosis and replication problems at the 
stem cell areas.  
 (A) Left panel: Hematoxylin & Eosin staining (H&E) and Villin immunostaining of TRF1
+/+
; Villin-
CreERT2
+/T
 and TRF1
lox/lox
; Villin-CreERT2
+/T
 intestines treated with 4-OHT showing moderate and 
severe permanent chronic lesions. In the treated intestines epithelial columnar absorptive cells 
disappear leading to a shortening of the villi (middle and lower pictures). In the severe cases, the 
epithelial lining is lost and a chronic inflammatory response is seen in mucosa and lamina propria 
(bottom pictures). Right panel picture: a representative H&E image showing apoptotic and 
endoreduplicated nuclei in TRF1
lox/lox
; Villin-CreERT2
+/T
 intestines upon treatment with 4-OHT (black 
arrows for apoptosis; blue arrow for endoreduplication). A close up picture of the designated area is also 
shown. (B) The number of crypts per optical field is significantly decreased in TRF1
lox/lox
; Villin-
CreERT2
+/T 
intestines compared to the TRF1
+/+
 mice. Indicated is the average number of crypts that are 
visible on a 200x magnification of an intestine, lined parallel to the picture border. Error bars, SEM; 
statistical comparisons were done using two sided student t-test.  (C&D) Percentage of apoptotic and 
endoreduplicated cells in the indicated crypt compartments and genotypes. The highest numbers of 
apoptotic and endoreduplicated nuclei are found at positions +4 to +7, which contain a putative stem cell 
population. Error bars, SEM; statistical comparisons were done using two sided student t-test.  
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Figure 28. TRF1 ablation induces DNA damage response 
(A) Graph of background (bg) reduced TRF1 intensities (in arbitrary units (a.u.)) per nucleus in TRF1
lox/lox
; 
Villin-CreERT2
+/T
 and TRF1
+/+
; Villin-CreERT2
+/T
 mice treated with 4-hydroxitamoxifen (4OHT) after 
immunofluorescence staining. There is a significant TRF1 intensity decrease upon ablation of TRF1 
expression. Almost no TRF1 could be detected in intestines from mice that showed atrophic intestinal 
structures with a chronic permanent lesions of the intestine, where no compartments could be identified. 
Error bars, SEM; statistical comparisons were done using two sided student t-test.  (B) Representative 
γH2AX and TRF1 immunofluorescence pictures of TRF1
lox/lox
; Villin-CreERT2
+/T
, and TRF1
+/+
; Villin-
CreERT2
+/T
 intestines. Arrows point to residual TRF1 in cells predominantly located at the +4 to +7 position. 
(C) Percentage of cells with 2 or more γH2AX foci is significantly increased in all compartments of the 
TRF1
lox/lox
; Villin-CreERT2
+/T 
intestines. Error bars, SEM; statistical comparisons were done using two sided 
student t-test. 
 
 
Next, we addressed whether increased apoptosis was associated with increased 
DNA damage upon TRF1 deletion (Martinez et al, 2009). We observed increased levels of 
γH2AX positive cells in all intestinal compartments with the highest amounts in epithelial cells 
from intestines with a chronic prominent lesion caused by Trf1 deletion (Fig. 27A&B). In 
addition, we observed increased abundance of telomere induced foci, which represent 
telomeres co-localizing with DNA damage foci (Fig. 27B&C), indicating that the DNA 
damage response induced by TRF1 ablation is most likely due to telomere dysfunction 
(Martinez et al, 2009). Intestines with moderate lesions shown in Fig 27B showed remaining 
TRF1 expression in their crypts (arrow), predominantly at the +4 to +7 positions. 
 
 
 
 
 
 
 
 
 
 
B A 
C 
  
Interestingly, we observed that TRF1 deletion also lead to a significant shortening of 
telomeres in all the intestinal compartments, with the most prominent shortening in the cells 
located at the +4 to +7 position of the crypts, containing a potential stem cell population (Fig. 
29A&B), suggesting increased duplication rates at the stem cell pools to compensate severe 
intestinal atrophy and severe cell loss owed to TRF1 ablation. 
 
B A 
C 
Figure 29. Telomere ablation leads to a hyperproliferative compensation of cells accompanied with 
telomere shortening and TIFs 
 (A) Graph of background corrected intensities per nucleus of Q-FISH labelled telomeres. We see in all 4 
intestinal compartments a decrease of telomere length. The most pronounced decrease is seen at the 
position +4 to +7 in the intestinal crypt. This finding points to a hyperproliferation of the cells in this region, 
possibly to compensate for severe intestinal atrophy as the consequence of TRF1 deletion. (B) 
Representative pictures of immuno-telomere Q-FISH on intestines of either genotype treated with 4OHT. 
An intestine with a chronic atrophic intestinal structure, where no compartments could be identified, is also 
included in the analysis (bottom). (C) Cells with 2 or more telomere induced foci (TIF, telomeres positive 
for 53bp1 foci). Statistical analysis was not always possible as in the wild-type condition as no TIFs were 
detected. Error bars, SEM; statistical comparisons were done using two sided student t-test.  Error bars, 
SEM; statistical comparisons were done using two sided student t-test. 
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José Alejandro Palacios 
Helping with the CHIP and co-IP experiments 
 
Miguel Foronda 
qRT-PCR analysis of lentiviral infected MEFs and ChIP-qRT-PCR 
 
Ianire Garrobo & Rosa Maria Marion 
Various reprogramming assays and knock-down experiments in the part about TRF1 being 
essential for nuclear reprogramming. 
 
Sagrario Ortega 
General help with teratoma and chimera formation assays.
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6.1 .  TH E  R AT I ON ALE  B EH IN D  TH E  GEN ER AT I O N  OF  TH E  E GFP-
TRF1  M OU SE  
Telomeric DNA is bound by a protein complex called shelterin. It protects chromosome 
ends from being recognized as a DSB by DNA repair mechanisms which would initiate cell 
cycle arrest and senescence or apoptosis. A key component of this shelterin protein complex 
is the telomere repeat binding factor 1. TRF1 binds the double stranded telomeric sequence 
acting as a scaffold for other shelterin proteins building up a protective, loop forming 
nucleoprotein structure at the chromosome ends. As TRF1 binds to the double stranded 
telomeric DNA, which makes up the majority of the telomere, it was expected that the 
amount of TRF1 would correlate with the telomere length (Chong et al, 1995; Zhong et al, 
1992). Based on this hypothesis we generated a mouse model that expresses a knocked-in 
eGFP tag in the TRF1 locus. This model would give us a tool to measure the telomere length 
indirectly, but in vivo.  
The analysis of TRF1 levels in murine and human skin samples of different ages clearly 
showed that TRF1 expression does decrease with age, which is in agreement with age 
dependent telomere shortening. However, analyzing the telomeres we could see that the 
telomere length decrease is much less pronounced when compared to the TRF1 expression 
drop (i.e. the amount of detected TRF1 per nucleus decreased by 40% whereas the amount 
of detected telomere repeats decreased around 10-fold less). These results suggested that 
different molecular mechanisms than telomere length underlie the regulation of TRF1 levels 
throughout life. The eGFP-TRF1 reporter mouse, even if it can only partially be used to follow 
telomere length, would give us a valuable tool to study the expression of TRF1 in normal and 
pathological conditions (i.e. ageing and cancer), the identification of new TRF1 partners and 
to track telomeres in living cells upon exposure to different agents and stimuli (i.e. FRAP 
assays under different conditions, telomere localization within the nucleus,...).  
 
6.2 .  TH E  EGFP-TRF1  FU S I ON  PR OTEIN  LOC AL I ZES  T O  TELOM ERES  
As in our mouse model the relatively big eGFP-Tag is fused to the TRF1 protein the 
proper localisation of the eGFP-TRF1 knock-in protein was not certain. The tag could 
stericaly shroud the DNA binding site or interfere with other important properties of the 
protein. Importantly, we could show in MEFs that the eGFP emission co-localizes with other 
factors of the shelterin complex, known to concentrate at the telomeres. This gave us the 
certainty that we can trace telomeres in vivo by the localization of the eGFP emission. This is 
useful for processes from which we know that the telomere localisation is of crucial 
importance such as the telomere aggregation and localisation at the nuclear lamina (Raz et 
al, 2008) or the inner nuclear envelope localisation in meiotic spermatocytes during the 
nuclear membrane polarisation (Scherthan et al, 2000; Siderakis & Tarsounas, 2007).  
 
6.3 .  EGFP-TRF1  FU S ION  PR OTE IN  B IN D S  TO  TEL OM ER IC  R EPE ATS  
AN D  IN TER AC TS  WI TH  T H E  K N OWN  SH ELTER IN  P R OTE IN S  
As seen by ChIP assay, the eGFP-TRF1 fusion protein is able to bind to the telomeric 
DNA. This excludes that the telomeric localisation of the fusion protein is conducted by other 
shelterin proteins that bind TRF1 (i.e. TIN2 (Kim et al, 1999)) and direct TRF1 to the shelterin 
complex without the necessity of eGFP-TRF1 to bind the telomeric DNA. Moreover, in a 
coimmunoprecipitation experiment followed by a mass spectrometry analysis we found that 
the eGFP-TRF1 fusion protein binds to the known binding partners and pulls down, with 
good scores, all the shelterin complex proteins that were also found in a wild-type TRF1 pull 
down.  This clearly indicates that the fusion protein is able to interact with its binding partners 
and that it can form dimers with endogenous TRF1 and with itself. This also indicates that the 
TRF1 binding site of the TRF-homology domain is not affected by the eGFP-tag (Fairall et al, 
2001). 
 
6.4 .  HYP OM OR PH IC  B EH AV I OU R  IN  TH E  EGFP-TRF1 -H OM O ZYGOU S 
M IC E  
The WT and the eGFP-TRF1/TRF1 heterozygous cells and mice do not show any 
phenotypical differences neither In-vitro nor in-vivo. However, the homozygous-KI genotype 
shows several phenotypes that are caused by the eGFP knock-in tag insertion. The most 
overt is the late embryonic lethality. This, if compared to the classical TRF1 knockout mouse 
that die at the blastocyst stage (Karlseder et al, 2003), indicates that the eGFP-TRF1 fusion 
protein is partially functional as embryos are viable until around day E13.5. The causes 
underlying embryonic lethality in the homozygous-KI mice are not known. In-vitro the 
homozygous-KI MEFs show an increased amount of multitelomeric signals (that represent 
stalled replication forks as described in (Martinez et al, 2009; Sfeir et al, 2009)), growth 
retardation and a lower efficiency of nuclear reprogramming. On the other hand, and in 
contrast to conditional TRF1-null cells, KI/KI cells are able to cycle, induce iPS cells that give 
raise to differentiated teratomas and contribute to chimerism and the tagged protein interacts 
with all the known shelterin complex proteins. In addition in eGFP-TRF1KI/KI cells, there was 
no indication of an activated DDR that would initiate senescence due to uncapped telomeres. 
The eGFP-TRF1 protein functionality could also be seen when eGFP-TRF1+/KI mice were 
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crossed with TRF1lox/lox; K5-Cre mice. The resulting TRF1eGFP-KI/∆; K5-Cre mice did not have 
the macroscopic phenotypes seen in TRF1lox/lox; K5-Cre mice. In contrast to TRF1∆/∆; K5-Cre 
mice that die perinatally, they showed normal hair growth, no hyperpigmentation and long 
time survival and normal weight (data not shown). This demonstrates that the eGFP-TRF1 
protein has at most a mild hypomorphic behaviour in stratified epithelia. However, the fact 
that the eGFP-TRF1 allele in homozygosis is embryonic lethal underscores the important 
role for TRF1 during embryogenesis where TRF1 not only has telomere capping functions 
(Karlseder et al, 2003). It is possible that the eGFP-tag at the amino terminal of the TRF1 
protein sterically interferes with the proper function of the TRF1 protein. As discussed above, 
eGFP-TRF1 localizes at the correct position indicating that the NLS as well as the DNA 
binding domain function properly. Given the fact that they are the most distant domains (in 
the primary protein structure) to the eGFP knock-in tag, the closer located TRFH and the 
acidic domain have a higher possibility to be affected by the eGFP-Tag (see Introduction Fig. 
5 and results Fig. 2). Of those, the TRFH domain seems to be fully functional as the shelterin 
complexing partner binding as well as the homodimerisation can be initiated with eGFP-
TRF1 protein. The only functional domain that is left to be possibly affected is the acidic 
domain at the N-terminus of TRF1 and the closest domain to the eGFP-tag.  
It has recently been shown that TRF2 is able to condense the telomeric DNA. The basic 
domain plays an important role for the execution of this function, and is located at the N-
terminus of TRF2, neutralizing the negative surface charge of the telomere DNA allowing its 
compaction into nucleosomes (Baker et al, 2011). The TRF1 acidic domain is found in the 
same position and exerts the opposite function. If this domain is absent or impaired, TRF1 is 
also able to condense DNA, pointing to the role of the TRF1 acidic domain in preserving the 
chromatin in a more open, plastic structure (Marion et al, 2009b; Poulet et al, 2011). 
Additionally, TRF2 is an inhibitor of the resolvase enzyme, an enzyme that is important in 
resolving of Holiday junctions, stalled replication forks and the opening of the T-loop that is 
recognized as a Holiday junction (Lewin et al, 2008; Poulet et al, 2009). If the eGFP-Tag 
indeed interferes with the acidic domain it might potentiate the resolvase inhibition, 
counteracting the cleavage of stalled replication forks and leave an increased number of 
stalled replication forks. These suggestions are in accordance with our findings of increased 
multitelomeric signals in the eGFP-TRF1KI/KI MEF and iPS cells that are detected by Q-FISH 
as multitelomeric signals (Sfeir et al, 2009). The fact that the eGFP-TRF1KI/KI MEFs are able 
to be reprogrammed and the lack of a phenotype, similar to that seen in TRF1-null mice, 
argues that the eGFP-TRF1 tag does not interfere with other TRF1 properties. 
In some experiments (i.e. western blots) we could see, that in the eGFP-TRF1+/KI 
samples the amount of eGFP-TRF1 is slightly lower if compared to the endogenous TRF1. 
This might indicate that there is a slight favouring for endogenous TRF1. On the other hand 
this might also be caused by the antibodies used that are unable to bind to their TRF1 
epitope by the eGFP-tag.  
In summary we can conclude, that eGFP-TRF1mice can be used in vitro and in vivo as a 
tool to follow telomeres, allowing a closer insight into TRF1 biology. However, it should be 
kept in mind that both homozygous-KI cells and mice (embryos) are influenced by eGFP-tag 
and show hypomorphic behaviour. 
 
6.5 .  TRF1  E X PR ESSION  D U R IN G N U C L E AR  R EPR OGR AM M ING  
We have shown that the amount of TRF1 bound to the telomeres is not directly 
correlated to the telomere length. Over age, the amount of TRF1 decreases to a higher 
extent than the amount of telomeric DNA repeats, suggesting that TRF1 expression as well 
as its binding to telomeres is not directly regulated by telomere length. To get a closer insight 
into the properties of TRF1 we decided to reprogram MEFs obtaining eGFP-TRF1 iPS cells. 
IPS cells express active telomerase and consequently elongate their telomeres (Marion et al, 
2009b). This gives us the possibility to study the behaviour of TRF1 during reprogramming 
and in pluripotency. Even though the reprogramming efficiency in eGFP-TRF1KI/KI is lower 
when compared to WT and heterozygous-KI, these cells were able to undergo nuclear 
reprogramming forming ES cell like colonies. From MEFs with the same telomere length in 
all the genotypes and only faint eGFP-TRF1 detection in heterozygous- and homozygous-KI, 
reprogramming initiated the telomerase dependent telomere elongation that lead to iPS cells 
with telomeres twice as long after seven passages.  Interestingly, at around 16 passages the 
KI/KI iPS cells abruptly abrogated their telomere elongation. The underlying mechanism of 
this observation remains to be elucidated and we can only speculate that the accumulation of 
multitelomeric signals inhibits a further elongation or that the interference of the eGFP-tag 
that in iPS cells is abundant in a higher density, sterically impairs the telomerase function.  
Comparing telomere lengths in iPS cells of all three genotypes with their corresponding 
eGFP emission, an unexpected but very interesting behaviour of the telomere bound TRF1 
could be observed. While the telomere lengths increased by approximately two fold at 
passages ≥7, the amount of telomere bound eGFP-TRF1 had increased to much higher 
extents at early passages after reprogramming. Further, the levels of eGFP-TRF1 remain 
high while telomeres keep elongating pointing to a yet unknown role of TRF1 in pluripotent 
cells. This hypothesis is supported by the observation that in aging skin, older skin loses its 
reproductive potential and simultaneously decreases the detectable TRF1 in a 
disproportional manner to the telomere length, suggesting a role of TRF1 in tissue 
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regeneration capacity. We could further show that the TRF1 upregulation is similar to the 
increase in Nanog and OCT3/4 levels during nuclear reprogramming. This is in agreement 
with a previous report showing that TRF1 is among the most upregulated genes associated 
with pluripotency and at that state going along with telomerase dependent telomere 
elongation (Boue et al, 2010). A final but important proof that the TRF1 expression is 
uncoupled from telomere length is the fact that during reprogramming of TPP1-null MEFs, 
TRF1 levels are also highly increased. This is striking as TPP1 is the shelterin complex 
protein responsible for bringing active telomerase to telomeres. TPP1-deficient cells are not 
able to elongate the telomeres after nuclear reprogramming (Tejera et al, 2010). These 
results clearly demonstrated for the first time that the levels of TRF1 are independent of 
telomere length. Nevertheless, this interesting new finding means that the eGFP-TRF1 
mouse model can no longer be used as an in vivo telomere measurement tool 
 
6.6 .  TRF1  IN D IC ATES  TH E PLU R IP OTEN CY POT EN TI AL  OF  A C ELL  
The fact that iPS cells from all the three genotypes are able to contribute to chimerism 
and induce teratomas that differentiate into the three germ layers, indicates a complete 
reprogramming of the parental MEF cells. In addition, the iPS-exome showed an increased 
expression of pluripotency markers such as OCT3/4 as well as Nanog. The latter is 
expressed at different levels in iPS cells of the same colony and marks proportionally the 
vigour of pluripotency (Chambers et al, 2007; Villasante et al, 2011). Following Nanog 
expression pattern of iPS cells, a similar pattern of the eGFP signal in the iPS colonies was 
encountered. Plotting the intensities of Nanog and eGFP-TRF1 against each another a 
significant positive correlation was revealed. In contrast, the expression of OCT3/4 was 
expressed homogeneously in iPS cell colonies. To investigate a possible correlation of TRF1 
with high pluripotency, iPS cells were sorted for their eGFP-TRF1 content. Cells that 
expressed a high level of TRF1, in contrast to iPS cell expressing low TRF1 levels, were 
successfully able to induce teratomas and to form chimeras. These results suggest that 
TRF1 expression correlates with pluripotency potential.  
EGFP-TRF1 expression in iPS cells sorted for high and low eGFP-TRF1 content was 
conserved from RNA transcription levels. The transcription of eGFP-TRF1 and Nanog mRNA 
showed the same high/low pattern on messenger RNA, whereas oct3/4 was transcribed to 
same extents in eGFP-TRF1high and eGFP-TRF1low iPS cells. Together with Nanog and 
eGFP-TRF1, mTert another stem cell indicator, was also found to be transcribed to higher 
levels in eGFP-TRF1high cells. These findings suggest that expression levels of TRF1 are 
correlated with increased pluripotency in iPS cells. 
 6.7 .  TRF1  IS  R EQU IR ED  D U R IN G R EPR OGR AM M IN G  
Importantly, we show here that high TRF1 levels are not only a marker for pluripotency 
as demonstrated by a higher ability to form teratomas and chimeric mice, but also that TRF1 
is essential both for reprogramming as well as for the maintenance of the pluripotent state.  
In particular, TRF1-deficient MEFs completely fail to be reprogrammed, even in the absence 
of p53 that has been shown to rescue cell growth (Marion et al, 2009a; Martinez et al, 2009). 
Furthermore, conditional deletion of TRF1 in already established iPS cells leads to rapid 
elimination of iPS cells coincidental with increased DNA damage and apoptosis. Whether this 
phenomenon occurs in a p53 dependant manner is not known as p53 might not be 
completely functional in ES or iPS cells (Hong & Stambrook, 2004; Tichy, 2011). However it 
demonstrates that the protection from telomere damage by TRF1 is essential for the 
maintenance of pluripotency. These results are in marked contrast with efficient 
reprogramming of cells with severe telomere shortening and uncapping due to telomerase- 
or TPP1-deficiency (Marion et al, 2009a; Tejera et al, 2010).  Together, these results suggest 
that TRF1 is an important factor for reprogramming of differentiated cells into induced 
pluripotent stem cells as well as for the maintenance of pluripotency. 
 
6.8 .  H I GH  LEVELS  O F  TRF1  M AR K  T ISSU E STEM  C ELLS  
C OM P AR TM EN TS  
Knowing that TRF1 plays an essential role in nuclear reprogramming and is highly 
expressed in pluripotent stem cells, we set to address the levels of eGFP-TRF1 in tissue. As 
expected, high levels of eGFP-TRF1 were detected in the known stem cell compartments of 
the skin and in the intestine. Moreover, if compared to telomere length, the decrease in TRF1 
levels in stem cells to differentiated cells was disproportional when compared to the telomere 
length decrease as seen by Flores et al. (2008) using very similar detection and analysis 
methods. In particular, in the small intestine where new stem cell pools are discovered 
frequently, we found differences in the various stem cell compartments in accordance to their 
stemness potential as determined by LGR5 and the position of the cells in the intestinal 
crypts (Barker et al, 2007; Montgomery et al, 2011; Schepers et al, 2011; Tian et al, 2011). 
Moreover, we could show with our fluorescence detection technique, that the LGR5+ cells, 
interspersing the LGR5-negative paneth cells do not have longer telomeres compared to the 
cells at the crypt positions +4 to +7. This is a marked contrast to the published results of 
(Sato et al, 2010) that suggest that the LGR5+ cells in the bottom of the crypt have the 
longest telomeres. Also in tail skin hair follicles we were able to demonstrate that the stem 
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cell pools for the sebaceous gland, the hair follicle and the epidermis express higher 
amounts of TRF1 if compared to the more differentiated cells in the same tissue. In 
conclusion we can say that in tissue, similar to iPS cells, TRF1 expression levels are a good 
marker for stemness within the same tissue. This change in levels is even more pronounced 
than telomere length differences and gives us a new marker to detect tissue stem cells. 
 
6.9 .  REGU L AT I ON  OF  TRF1  EXPR ESSION  I N  I PS  AN D  ES  C ELLS  
We showed that TRF1 in ES and iPS cells is upregulated in a telomere length 
independent manner. Therefore we set to address the reason for this upregulation. From 
previous research we know that the promoter region of TRF1 has a potential binding site for 
OCT3/4 (Loh et al, 2006). A functional assay, expressing OCT3/4 in MEFS as well as a CHIP 
followed by a q-RT-PCR gave us proof that OCT3/4 is indeed able to initiate TRF1 
transcription by binding to its promoter region. However, the trf1 levels did not reach the 
levels of trf1-mRNA in iPS cells. This suggests that the OCT3/4 dependent increase of TRF1 
expression is not the only mechanism for increased TRF1 transcription. In our q-RT-PCR 
Nanog did not bind the analyzed promoter region, but in a ChIP-PET assay done by Loh et 
al. (2006) Nanog binds to TRF1 with four overlapping PETs suggesting a very high 
interaction probability. It is therefore fair to speculate that Nanog itself or Nanog dependent 
downstream factors are responsible for a further increase in TRF1 expression. This would 
explain the heterogeneous expression pattern of TRF1 in iPS colonies and the similar 
characteristics of eGFP-TRF1high and Nanoghigh iPS cells.  
 
6.10.   CON D IT I ON AL  AB L AT I ON  OF  TRF1  I N  TH E  SM ALL  
I N TEST IN E  
To demonstrate that TRF1 expression is essential for the maintenance of tissue 
homeostasis we generated a new mouse model where we conditionally deleted TRF1 in the 
villin expressing tissues. This led to the disruption of the tissue homeostasis similar as 
observed in skin (Martinez et al, 2009). As long as TRF1 in the stem cell population in crypts 
was maintained above a critical threshold, the crypt/villi morphology was not disrupted, even 
though shorter villis and an increased uncapping of telomeres were detected. Interestingly 
however, as soon as all the cells in a crypt lost the functional TRF1 alleles, the intestine 
completely collapsed and lost its structure and functions. This was accompanied by intestinal 
atrophy, diffuse inflammatory infiltration and weight loss of mice in which the main parts of 
their intestines showed TRF1 deficiencies. Interestingly, crypts with a moderate phenotype 
showed severe telomere shortening. The highest amount of telomere shortening was 
observed in position +4 to +7, the sites where we observed the highest amounts of TRF1 
under normal conditions and where the slow cycling stem cells are present. This points to the 
immense importance of the intestinal stem cells and their requirement to replenish lost cells 
that either undergo apoptosis or get lost in the intestinal epithelium due to senescence and 
mechanical loss. It also shows that the constant proliferating pressure on stem cells leads to 
a compensatory telomere shortening in stem cells and together with the mentioned finding 
that all remaining crypts have stem cells with TRF1 underlines the importance of TRF1 in 
intestinal tissue homeostasis and stem cells. 
  
 In summary, we describe here new roles for the telomere protective protein, TRF1, in 
adult stem cells as well as pluripotent stem cells, that are independent of telomere length and 
which highlight an essential role for telomere protection mediated by TRF1 in stem cell 
biology. On the one hand, high TRF1 levels mark adult stem cell compartments as well as 
pluripotent stem cells. Moreover, TRF1 is essential for both, maintenance of adult stem cell 
compartments of intestine and skin, as well as for the induction and maintenance of 
pluripotency in iPS cells. Supporting the notion that TRF1 is a key factor for pluripotency we 
make the unprecedented finding that TRF1 is a direct target of OCT3/4, which binds to the 
TRF1 promoter and is sufficient to upregulate TRF1, thus providing a mechanistic link 
between TRF1 and pluripotency. 
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7.  CO N C L U S I O N S  
 
 
 
1. An eGFP-TRF1 knock in mouse model was generated where the eGFP-tag is located 
in exon 1 just behind the ATG start-codon. 
2. The expressed eGFP-TRF1 fusion protein binds to telomeric DNA and allows us to 
follow the telomeres and TRF1 protein in vivo and in vitro by the eGFP emitted signal 
but shows a hypomorphic phenotype in the homozygous knock in. 
3. TRF1 levels are highly upregulated in induced pluripotent stem cells in a telomere 
independent manner. This is partially due to the activation by the pluripotency 
transcription factor OCT3/4 by binding the TRF1 promoter region. 
4. In iPS cell colonies, TRF1 expression correlates with the Nanog expression and 
indicates a higher level of pluripotency within iPS colonies. Therefore, the sorting of 
eGFP-TRF1high cells allows us to distinguish between more pluripotent iPS cells when 
compared to eGFP-TRF1low iPS cells. 
5. Tissue stem cells of skin and intestine have elevated levels of TRF1 abundant at their 
telomeres. The high increase of TRF1 in those cells is independent from telomere 
length. 
6. TRF1 is essential for the induction and maintenance of pluripotency as its deletion 
inhibits pluripotency by established reprogramming factors and conditional ablation of 
TRF1 leads to loss of viability in iPS cells. 
7. TRF1 is essential for small intestine homeostasis. Its deletion induces inflammation 
and apoptosis induced by DNA damage response pathways, leading to complete 
destruction of the crypt/villi morphology. 
8. TRF1 loss in the small intestine induces telomere shortening, most prominent in the 
stem cell position, most likely due to compensatory hyperproliferation replenishing the 
lost cells. 
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8.1 .  GEN ER ATI ON  OF  TH E  E GFP-TRF1  KN OC K - IN  M OU SE M OD EL  
 The targeting construct and mice with the targeted TRF1 allele were generated by 
genOway (France; as seen in result part Fig. 2A) using standard procedures. The neomycin-
resistance (NEO) cassette was excised by crossing with mice carrying the Cre-recombinase. 
Wild-type, eGFP-TRF1+/KI and eGFP-TRF1KI/KI mice were generated and maintained at the 
CNIO mouse facility.   
 Genotyping of the eGFP-TRF1 allele was performed by PCR as depicted with primers 
flanking the possible eGFP-cassette.   
Forward Primer: 5’-CAGGGTTAAATGCTCATGTTTATGGCG-3’  
Reverse Primer: 5’-TGCTCTGGAGAATCCGAATCTGTCC-3’ 
 
8.2 .  GEN ER ATI ON  OF  MEFS   
Primary MEFs were isolated from E13.5 or E11.5 embryos. Briefly: Uterus was removed 
and put into PBS with antibiotic at 37°C. Uterus wall was cut to take out the embryos. Liver 
was removed as well as a part of the head (for genotyping). Embryo was chopped in a 6cm 
dish with a razorblade in 2x trypsin (Invitrogen 25300-054) in PBS, incubated at 37°C for 
20min, dispersed with a Pasteur pipette and incubated for another 20min. Cells were further 
transferred to a 10cm dish and grown with 15ml DMEM (Invitrogen 31966021) with 10%FCS 
(Dundee cell products LTD DS1003) and standard tissue culture antibiotics (Gibco 15240). 
 
8.3 .  GEN ER ATI ON  OF  IPS  C ELLS  
 Reprogramming of eGFP-TRF1 iPS cells from the indicated genotypes was 
performed as described by (Blelloch et al, 2007). The cells (like all the iPS cells described in 
this thesis) were grown in full iPS medium (DMEM; Invitrogen 31966021) supplemented with 
15% KSR (Knockout Serum Replacement; Invitrogen 10828028) + LIF (1000U/ml; 
ESGROTM, Millipore ESG1107) + non-essential amino acids (MEM Non-Essential 
Aminoacids Solution; 1X; Invitrogen 11140035) + 2-mercaptoethanol (0.5 mM; Invitrogen 
31350) + Pen/Strep (1X) on gelatin coated plates. Medium was changed daily and at 70-80% 
of confluence cells were trypsinized and passed onto a new dish with a 1:7 dilution. 
The generation Tpp1∆/∆ iPS cells have been described before by (Tejera et al, 
2010).  TRF1lox/lox; p53-/- and TRF1+/+; p53-/- MEFs were infected once with retroviral Cre-
recombinase as previously described (Martinez et al, 2009). Puromycin (2µg/mL; Sigma-
Aldrich P8833) selection was added 48 hours after the infection. Selected cells were 
reprogrammed as previously described (Marion et al, 2009a). Obtained iPS colonies were 
picked 2-3 weeks after infection and expanded on feeder fibroblasts. Feeder fibroblasts were 
generated by exposition 2x107 to 6x107 cells/ml in a 50ml Falcon tube to a gamma ray 
emitting source at a total dose of 3000 rads. 
Reprogramming and generation of TRF1-null iPS cells. We reprogrammed 
TRF1lox/lox and TRF1+/+; RERTn+/ERT MEFs (Guerra et al, 2003) as described above. The 
resulting iPS clones were picked and treated with 4-hydroxytamoxifen (Sigma-Aldrich 10013) 
to obtain TRF1/ and TRF1+/+ iPS cells, respectively. IPS from both genotypes were seeded 
at low density (50,000 cells per well in 6well-plates) on feeders or gelatin coated (for qRT-
PCR analysis) dishes and treated with 4-hydroxytamoxifen at a final concentration of 0.2M 
in complete iPS medium, which was replaced daily.  
TRF1 deletion in iPS cells was obtained from TRF1lox/lox; p53-/- Cre MEFs. The 
Genotype was checked by PCR with:   
Forward primer: E1-popout 5′-ATAGTGATCAAAATGTGGTCCTGGG-3′  
Reverse primer: SA1 5′-GCTTGCCAAATTGGGTTGG-3′. 
 Efficiency of reprogramming was determined by alkaline phosphatase activity (AP 
detection kit, Chemicon International), following the manufacturer’s instruction. 
 
8.4 .  CH IM ER A FORM ATI ON  
 The ability of the iPS clones to generate chimeras in vivo was tested by aggregation 
with CD1 (albino) morulae following standard procedures as described in (Marion et al, 
2009b). At least two independent iPS clones from each genotype (sorted and unsorted) were 
tested. 
 
8.5 .  WESTER N  B LOTT IN G  
 Whole cell and nuclear protein extracts as described by (Martinez et al, 2009), were 
used for western blot analysis. Protein concentration was determined using the Bio-Rad DC 
Protein Assay (Bio-Rad). Up to 25µg of protein per extract were separated in SDS–
polyacrylamide gels by electrophoresis. After protein transfer onto nitrocellulose membrane 
(Whatman), the membranes were incubated with the indicated antibodies (see below). 
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Antibody binding was detected after incubation with a secondary antibody coupled to 
horseradish peroxidase using chemiluminescence with the ECL detection KIT (GE 
Healthcare) or by antibodies coupled to Alexa680 (Invitrogen) emitting light at 700nm upon 
excitation. Detection was performed on an Odyssey Clx (Li-COR) infrared detector. 
  
Antigen Dilution Providor Product number 
Nanog 1:5000  Millipore AB5731 
Actin 1:7500 Sigma a2228 
eGFP 1:1800 Invitrogen a11122 
eGFP 1:3000 Clontech JL8 632380 
Oct3/4 1:500 Santa Cruz sc-9081 
SMC1 1:1000 Bethyl A300-055A 
TRF1 1:5000 Abcam ab-10579 
Villin 1:5000 Dako M3637 
 
 
8.6 .  IM M U N OST AIN IN GS ON  MEFS ,  IPS  C ELLS ,  AN D  T ISSU E 
SEC T I ON S  
 Cells were grown on gelatin covered glass bottom dishes (24 well plates; MatTek). 
Cells and OCT sections were fixed with 4% formaldehyde in PBS for 8min at 37°C, 
permeabilized in 0.5%Triton-X100 in PBS and blocked with 100% Australian FBS 
(GENYCELL) for 40min at room temperature (RT).  
 Paraffin Tissue sections were deparaffinised and a citrate antigen retrieval was 
performed at pH 6.5 (TRF1) or with CC1M-Buffer (Ventana). For direct eGFP-TRF1 detection 
combined with an immunostaining fresh frozen tissue sections (14µm) from tissue embedded 
in tissue freezing medium (Jung) were used. Sections were further blocked with 100% 
Australian FBS (GENYCELL) for 40min at RT.  
The antibodies for all tissues and cells were applied overnight at 4ºC in antibody diluents with 
background reducing agents (Invitrogen). Primary antibodies used see table. Secondary 
antibody incubation was performed after three 5min washing steps with PBS for 40min at RT. 
The nuclei were counterstained in a 4µg/ml DAPI/PBS solution before mounting with 
Vectashield (Vector). 
 8 . 6 . 1 .  P R I M A R Y  A N T I B O D I E S  
   Antigen Dilution Providor Product number 
GFP 1:500 Roche 11814460001 
Nanog  1:180 Novus NB100-58842 
Oct3/4 1:180 Santa Cruz sc-9081 
TRF1 1:250 Homemade by Munoz et al., 2005 
TPP1 1:200 Gift Dr. Else, University of Michigan 
Rap1 1:100 Bethyl A300-306A 
γH2AX  1:500 Millipore 05-636 
53BP1 1:200 Novus NB100-304 
 
8.7 .  ST AN D AR D  Q-FISH  PR OTOC OL  
 Slides were washed in PBS and further fixed in 4% formaldehyde (Sigma)/PBS for 
2min followed by a 3x5min washing step with PBS.  Slides were further incubated in 0.1% 
porcine pepsine (Sigma), 0.01M HCL (Merck) for 10min at 37°C, washed with PBS and 
another fixing and washing step was performed. Slides were then dehydrated in 70%, 90% 
and 100% Ethanol dilutions. Slides were further air dried and the Q-FISH labelling probe mix 
was applied. The probe mix consists of 10mM Tris, 25mM MgCl, 9mM citric acid, 82mM 
Na2HPO4 (adjusted to pH 7), 70% deionised formamide (Sigma), 0.25% blocking reagent 
(Roche) and 0.5µg/ml Telomeric PNA-probe (Panagene). Slides were further covered with a 
cover slip and the DNA was denatured on a pre-warmed heating plate at 85°C for 3min. 
Slides were then incubated for 3 hours in a wet chamber at RT , followed by a 2x15min 
washing step in 70% formamide, 10mM Tris and 0.1% BSA (Sigma). After another 2 x 15min 
of washing with 0.08% Tween20 (Sigma)/TBS slides were incubated in a 4µg/ml dapi 
(Sigma) solution and mounted with Vectashield (VectorTM) 
Telomeric PNA-probe was generated at Panagene directed against telomeric repeats. The 
PNA sequence is: Cy3-00-CCCTAACCCTAACCCTAA-Lys 
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8.8 .  TELOM ER E LEN GTH  AN D  C YT O GEN ETIC  AN AL YS IS  U S IN G 
TELOM ER E Q-FISH  ON  M ET APH AS ES  AN D  IN TER PH ASES  
For metaphase Q-FISH analysis, cells were incubated with 0.1 mg/ml colcemide 
(Gibco) for 4 h at 37°C, swollen in hypotonic buffer (10mMTris-HCL at pH 7.5, 10mM NaCl, 
5mM MgCl2) for 10 min at 37°C, and fixed with methanol/acetic acid as described in (Samper 
et al, 2001). Metaphases were dropped onto slides and the Q-FISH protocol was performed 
as described above. For the determination of the telomere length we used the TFL-Telo 
software (Zijlmans et al, 1997). The metaphases were additionally scored by eye for the 
presence of multitelomeric signals and sister type chromatid fusions by superimposing the 
telomere image on the DAPI chromosome image. Where telomere lengths are indicated, the 
values were calculated by a linear correlation to L5278-R cells (r-cell). Their telomere length 
remains stable and was determined before at 79.4kb of length (Canela et al, 2007b). 
 For interphase Q-FISH analysis, MEFs and iPS cells were plated on gelatin covered 
glass bottom dishes (24well plates; MatTek) and fixed with methanol/acetic acid (3:1). A 
standard Q-FISH protocol was performed as described above but in the case of iPS cell 
colonies the denaturation step was carried out in a water bath at 80°C and the  PNA probe 
incubation step was repeated after two hours of incubation. The total PNA probe incubation 
was increased to a total of 6 hours in the case of iPS cell colonies to get a good diffusion of 
PNA probe through the colonies. Where telomere lengths are indicated, the values were 
calculated by a linear correlation to L5278-R cells (r-cell). Their telomere length remains 
stable and was determined before at 79.4kb of length (Canela et al, 2007b). 
 
8.9 .  IM M U N OFISH 
 In cells, immunostainings were performed as described above. After washing the 
excess of secondary antibodies with PBS, cells were fixed in 4% formaldehyde/PBS for 
2min, dehydrated with ethanol, and incubated with the PNA probe against telomeric repeats 
labelled with CY3 (Panagene). The probe was thereby diluted in only 50% of formamide 
instead of 70% as described in the standard Q-FISH protocol. The technique is also 
described in (Gonzalo et al, 2006; Samper et al, 2001). 
 In tissues, as a first step the telomeric Q-FISH was performed using citrate antigen 
retrieval (10 mM sodium citrate (pH 6.5) cooked under pressure for 2 min) instead of pepsin 
antigen retrieval avoiding complete digestion of antigens. Further the slides, without 
formaldehyde fixation, were dehydrated by decreasing ethanol dilutions as seen in the 
standard protocol, air dried and the PNA incubation step followed as described above. After 
the first washing steps with formamide a normal immunostaining was performed as 
described in the paragraph for immunostainings for tissues. No additional antigen retrieval 
was applied. 
 
8.10.  M IC R OSC OPY  
 Image acquisition: Fluorescence staining as well as the endogenous eGFP-TRF1 
emission and the Q-FISH were acquired in a confocal high-resolution Leica TCS-SP5 
(AOBS) microscope. 8-bit image layer stacks were taken with a step size of 0.8 µm and 
maximum projected by the LAS AF (Leica) software for analysis.   
The metaphase Q-FISH was acquired with a Fluorescence microscope (Leica DM RA2) at 
1000x for telomere measurement with TFL Telo software as described above. 
 Segmentation and quantification of objects for the analysis of fluorescence 
intensities of all stainings that were analyzed was performed with Definiens Developer 
XD1.2, XD 1.5 or XD 2.0 software (Definiens). Nuclei and spots were segmented with 
cellenger and developer algorithms or by hand. Algorithms were written by hand and are 
available upon request. Intensities were exported with an own made developer ruleset into 
excel readable files (rulesets are not published in this thesis but information about them can 
be asked at www.lifelength.com). Where indicated the intensities, were converted into heat-
maps of the different tissues with the Definiens Developer using an own made algorithm 
calculating the indicated fluorescence intensity percentiles and assigning the colour code 
fully automated. Lgr5-GFP positive nuclei in the intestine and tail skin were selected by hand 
for further analysis of their nuclei. 
 The quantification of eGFP-TRF1 in mouse tissue was done on fresh frozen tissue. 
The tissue cuts as well as cells were fixed in 4% PFA/PBS for 4min at 37ºC washed in PBS 
and embedded with Vectashield (Vector). Pictures were acquired on the same day to avoid 
signal intensity losses by eGFP degradation. The analysis was done with an own made 
Definiens Developer algorithm including a background reduction taking into account the 
mean, non-spot green-channel intensity per nucleus due to the high  autofluorescence in the 
eGFP emitting spectrum. 
 Quantification of TIFs in TRF∆/∆ intestines has been analyzed by an automated 
costaining-analysis with an own made Definiens algorithm after a Cellenger spot-
segmentation for Telomeres (red) and 53bp1 foci (green). Telomeres that overlapped with 
53bp1 Foci were considered as TIFs. 
  
E
x
p
e
ri
m
e
n
ta
l 
P
ro
c
e
d
u
re
s
 
8.11.  PR EP AR AT I ON  OF  N U C LEA R  EXTR AC T FOR  
IM M U N OPR EC IP IT AT ION  AN D  M ASS SPEC TR OSC OP Y AN AL S YS IS  
eGFP-TRF1 KI/KI, KI/+ and +/+ iPS cells (1.50 x 107) were resuspended in 15mL of 
osmotic buffer (10mM Hepes pH 7.5, 210mM manitol, 70mM sucrose, 1mM EDTA, 1X 
protease inhibitor cocktail (Sigma), 1mM NaVO4, 5mM beta-glycerophosphate, 0.1 M PMSF, 
5mM NaF) and cytoplasmic membrane was broken using a Dounce homogenizer. Nuclei 
were pelleted by centrifugation at 800g for 10min at 4°C, resuspended in 1mL of RIPA buffer 
(150mM NaCl, 10mM Tris pH 7.5, 0.1% SDS, 1% Triton, 1% deoxycholate, 5mM EDTA) and 
lyzed for 30min in a rotating wheel for 30min at 4°C. Nuclear lysate was sheared by 
sonication during for 15min (30s ON and 30s OFF) and then cleared by centrifugation at 
13000rpm for 15min. Total nuclear lysates were immnunoprecipitad using µMACS™ GFP 
Tagged Protein Isolation Kit (Miltenyibiotec; 130-091-125). Immunoprecipitated complexes 
were digested following the FASP protocol (Wisniewski et al, 2009) using sequentially LysC 
(Wako) and Trypsin (Trypsin Gold, Promega). Peptides were loaded in a Reprosil AQ Pur 
C18 (250mm x 0.075mm) capillary column (Dr. Maisch GmBH) with 0.1% formic acid and 
separated at a flow of 300ml/min in a 175min linear gradient generated by an Eksigent 
nanoLCultra 1D+ (Eksigent). The column was directly coupled to a LTQ-Orbitrap-Velos mass 
spectrometer through a 20µm I.D., 10µm tip, silica PicoTip nanospray emitter (New 
Objective) operated at 1.8kV. The mass spectrometer was programmed to acquire spectra in 
a data dependent mode. The survey scans were acquired in the Orbitrap mass analyzer with 
resolution 60,000 at m/z 400 with lock mass option enabled for the 445.120024 ion. For each 
MS scan, up to the 15 most intense peaks with charge state ≥2 and above an intensity 
threshold of 1000 were selected for sequencing and fragmented in the ion trap by collision 
induced dissociation with normalized collision energy of 40%, activation q=0.25, activation 
time of 10ms, and one microscan. To minimize redundant sequence of peptides, masses 
sequenced more than once were dynamically excluded for 60 sec. 
The raw data generated was processed with the Protein discoverer program 1.2 
(Thermo). Database search was performed by MASCOT 2.2 search engine 
(www.matrixscience.com) interrogating the IPI_mouse database V3.81 (Mar2011) 59,593 
entries with a precursor tolerance of 10ppm and fragment tolerance of 0.3Da. The search 
considered cysteine carbamidomethylation as fixed modification, oxidation of methionine as 
variable modification and allowed up to two missed cleavages for protease. Only peptides 
and proteins with a FDR lower than 1% were considered for identification. 
 
8.12.  FLOW  C YTOM ETR Y AN AL YS IS  
 Trypsinized iPS cells grown in KSR-ES-medium were washed in PBS supplemented 
with 1% FBS, fixed in 3% PFA  (Sigma) at RT for 15min and permeabilised with PBS +0.1% 
Triton-X100 (Sigma) followed by a PBS + 1% FBS blocking step.  Nanog expression was 
determined using an α-Nanog antibody at 1:200 dilution (Novus; NB100-58842) at RT for 
45min, followed by a secondary antibody labelled with AlexaF647.  
 SSEA-1 expression during reprogramming was assessed by flow cytometry, as 
previously described (Li et al., 2009).  
 Samples were acquired on a FACS Canto-II or a LSRII Fortessa (for SSEA-1) (BD, 
San Jose, CA) using pulse processing to exclude cell aggregates and debris. At least 20’000 
events were collected per sample. Data was analyzed using FlowJo Software v.9.1 
(Treestar, Eugene, OR).  
 
8.13.  FLU OR ESC ENC E AC T IV AT E D  C ELL  SOR T IN G  
 IPS cells were trypsinized and washed in PBS supplemented with 1% FBS and re-
suspended in DMEM 1unit/ml LIF, 3% KSR and 3mM EDTA. Wild-type, eGFP-TRF1+/KI and 
eGFP-TRF1KI/KI cells were FACS sorted on an Aria II (BD, San Jose, CA) according to their 
eGFP-TRF1 levels of expression into high and low fraction (1/1). Cell aggregates and dead 
cells were excluded by using pulse processing and DAPI. 1x106 cells for each fraction were 
collected, centrifuged, washed with PBS and prepared for following experiments. 
 For eGFP-TRF1-level dependent teratoma and chimera formation: iPS cells were 
grown on feeders. For all the experiments, the cells were trypsinized and incubated with 
10µg/ml Hoechst (Invitrogen H1399) in iPS medium at a concentration of 1x106 cells/ml for 
30min at 37°C. Tubes were sporadically shaken to increase the Hoechst uptake. Cells were 
further filtered to evade aggregates and sorted for the G1 phase and eGFP-TRF1 amount. In 
Fig. 1, the sorting strategy is depicted. Only cells in from the G1 phase were analyzed due to 
the increased amount of DNA and telomere ends giving additional binding sites for the 
eGFP-TRF1 increasing the eGFP-intensity in S and G2 cell cycle phases. 
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Fig. 1: eGFP-TRF1 cell sorting strategy. 
Visible on top are cells incubated with 
Hoechst for depicting the cell cyle. Cells 
from the G1 peak were further separated 
into cells with high and low eGFP-TRF1 
intensity; depicted in red and green in the 
left panel. In the bottom right panel, cells 
that were used for Teratoma and chimera 
formation are lined in the dotted rectangle. 
 
 
8.14.  TER ATOM A F ORM AT I O N  
 IPS-cells were sorted as described above. 1.5x106 cells were directly after the sorting 
concentrated to 100µl of PBS and subcutaneously injected into the flanks of nude mice, 
according to their amount of eGFP-TRF1.  For the unsorted teratoma assay, 2x106 untreated 
and unsorted iPS cells in PBS suspension were injected into the flanks of nude mice. The 
variation of the cells is explained by the fact that not more than 1.5x106 could be sorted 
without drawback on the cell viability.   
 
8.15.  QU AN T IT AT IVE  R EAL -T IM E PCR 
 Total RNA from cells was extracted with Trizol (Life Technologies). Samples were 
treated with DNase I before reverse transcription. Reverse Transcription was done using 
random priming and iScriptTM (BioRad) according to the manufacturer’s protocol (eGFP-
TRF1-iPS cells) or using Ready-To-Go You-Prime First-Strand Beads kit (GE Healthcare) 
according to the manucafturer’s protocl.  
Quantitative real-time PCR was performed with an ABI PRISM 7700 (Applied Biosystems), 
using DNA Master SYBR Green I mix (Applied Biosystems) according to the manufacturers 
protocol. All values were obtained in triplicates. 
Primers used:  
mNanog-F, 5’-AGGGTCTGCTACTGAGATGCTCTG-3’;  
mNanog-R, 5’-CAACCACTGGTTTTTCTGCCACCG-3’;  
mEndoOct3/4-R, 5’-TGCGGGCGGACATGGGGAGATCC-3’; 
mEndoOCT3/4-F, 5’-TCTTTCCACCAGGCCCCCGGCTC-3’; 
mTERT-F, 5’-GGATTGCCACTGGCTCCG-3’; 
mTERT-R, 5’-TGCCTGACCTCCTCTTGTGAC-3’; 
eGFP-TRF1-F, 5’-CCTGAGCAAAGACCCCAAC-3’; 
eGFP-TRF1-R, 5’-TCCTCCTGCTCTGGAGAATC-3’. 
mTRF1-F: 5’-GTCTCTGTGCCGAGCCTTC-3’; 
mTRF1-R: 5’-TCAATTGGTAAGCTGTAAGTCTGTG-3’; 
Gapdh-F, 5’-TTCACCACCATGGAGAAGGC-3’;  
Gapdh-R, 5’-CCCTTTTGGCTCCACCCT-3’; 
TRF1-Pr-F: GAAGGGGAAGAGGGAGTGAG 
TRF1-Pr-R: TTGTCAGGCACCTGTCTCAG 
TRF1-PrCtrlRegion-F: TCAGGAATGTCCCCTGAGAT 
TRF1-PrCtrlRegion-R: GCATTCCCTTCGGGTATTTT 
Nanog-Pr-F: GAAGGGGAAGAGGGAGTGAG 
Nanog-Pr-R: TTGTCAGGCACCTGTCTCAG 
OCT3/4-Pr-F: CTCTCGTCCTAGCCCTTCCT 
OCT3/4-Pr-R: CCTCCACTCTGTCATGCTCA 
Calculations were made using the Ct method as described (Yuan et al, 2006). 
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8.16.  IN FEC T ION  OF  MEFS  FOR  TRF1  M RNA  AM OU N T 
M E ASU R EM EN T  
Two days before infection, 4x105 293T cells were transfected with Fugene6  (Roche) 
following manufacturer’s instructions and using 4 mg of pCL-Eco and 4 mg of each plasmid 
of interest (pMX-Sox2, pMX-KLF4 or pMX-OCT3/4). The day after, MEF were seeded at a 
density of 2x105 cells in a p35 well and fresh media wash added to the 293T cells. The 
following day medium was collected, filtered through a 0,45mm filter and 8mg/ml polybrene 
was added; 1ml of filtered medium was added to each well containing the MEF seeded the 
day before; infection was repeated every twelve hours, to a total of four times and cells were 
harvested three days after the last infection for RNA isolation and subsequent qRT-PCR 
analysis.  
 
8.17.  EGFP-TRF1  CH IP  AS S AY  
ChIP assays were performed as previously described (Garcia-Cao et al, 2004). In 
brief, after cross-linking and sonication, chromatin from 4x106 cells were used per each 
immunoprecipitation with protein anti-GFP agarose beads (MBL International, D-153-8) and 
the following antibodies: 6 µg of anti-histone H3 (# ab1791, Abcam), 8 µl of polyclonal rabbit 
anti-TRF1 serum at (homemade and described in (Munoz et al, 2005)). The 
immunoprecipitated DNA was transferred to a Hybond N+ membrane using a dot blot 
apparatus. The membrane was then hybridized with either a telomeric probe containing 
TTAGGG repeats or a probe recognizing major satellite sequences, which is characteristic of 
pericentric heterochromatin. Quantification of the signal was performed with ImageJ software 
(NIH). The amount of telomeric and pericentric DNA after ChIP was normalized for the total 
telomeric DNA. 
 
8.18.  CH R OM AT IN  IM M U N OPR EC IP IT AT ION  F OLL OWED B Y 
QU AN TIT AT I VE  R EAL -T IM E PCR  (CH IP  QRT-PCR).  
 ChIP-qPCR was performed as previously described by (Martinez et al, 2010). A total 
of 20 ng of total DNA were used in each qPCR reaction. SYBR-green reagent was used for 
qPCR following manufacturer’s instructions. Ct for every amplified region was normalized to 
its corresponding INPUT Ct, taking into account sample dilution for data representation. 
Antibodies used: Nanog 4µg (Novus; NB100-58842); Oct3/4 µg (Santa Cruz sc-9081). 
 8.19.  FBS-M ED IUM  C U LTU R IN G  OF  IPS  C ELLS  
iPS cells  at passage 4 and 5 were grown in Medium (DMEM; Invitrogen 31966021) 
supplemented with 15% KSR (Knockout Serum Replacement; Invitrogen 10828028) + LIF 
(1000U/ml; ESGROTM, Millipore ESG1107) + non-essential amino acids MEM Non-
Essential Aminoacids Solution (1X; Invitrogen 11140035) + 2-mercaptoethanol (0.5 mM; 
Invitrogen 31350) + Pen/Strep (1X) on gelatin coated plates. Cells were trypsinised and 
50’000 cells of each clone were seeded in gelatin coated 6-well plate wells. The control cells 
were cultured under KSR-medium conditions as explained in the reprogramming section. 
The other cells were grown in medium containing LIF and 15% of FBS (ES cell tested) 
instead of KSR. The medium was changed daily. For flow cytometry analysis and cell count 
by Neubauer cytometer, samples were collected by trypsinisation. For flow cytometry 
analysis the cells were washed twice in PBS and incubated with DAPI to exclude dead cells. 
Cell for analysis were resuspended in PBS containing 1% of BSA and 1mM EDTA. Pictures 
were captured on a bright field microscope with 100x magnification. 
 
 
8.20.  LEN TIV IR AL  TR AN SD U C TI ON S  OF  TH E  SH RNAS   
 Experiments were performed on MEFs from p53-/- embryos (MEFs, of C57BL6 genetic 
background) reprogramming was performed as described above. Lentiviral transduction: 
Retroviral supernatants were produced in HEK-293T cells (ATCC® Number CRL-11268™) 
(5x106 cells per 100-mm-diameter dish) transfected with the ecotropic packaging plasmid 
pCL-Eco (4 µg) together with either one of the following retroviral constructs (4 µg), pMXs-
Klf4, pMXs-Sox2 or pMXs-Oct3/4 (obtained from Addgene) or pBabe Hygro (kindly donated 
by Francisco Real). Similarly, lentiviral supernatants were produced in HEK-293T cells 
(5x106 cells per 100-mm-diameter dish) transfected with the packaging plasmids 
pMDLg/pRRE (3.25 µg), pRSV.Rev (1.25 µg), pMD2.G VSVG (1.75 µg) (obtained from 
Addgene), and either one of the following shRNA lentiviral constructs (5 µg), pLKO.1-puro-
scramble shRNA (obtained from Addgene) or pLKO.1-puro-TRF1 shRNA (bacterial glicerol 
stock (TRCM0000071298, obtained from Sigma-Aldrich). Transfections were performed 
using Fugene-6 transfection reagent (Roche) according to the manufacturer’s protocol. Two 
days later, viral supernatants (10 ml) were collected serially during the subsequent 48 hours, 
at 12 hour intervals, each time adding fresh medium to the cells (10 ml). The recipient MEFs 
had been seeded the previous day (2x105 cells per 60-mm-diameter dish) and received 1 ml 
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of each of the corresponding viral supernatants. The following viral cocktails were used: 
pBabe Hygro and pLKO.1-puro-scramble shRNA (mock-scrambled), pBabe Hygro and 
pLKO.1-puro-TRF1 shRNA (mock-shTRF1), pMXs-Klf4, pMXs-Sox2, pMXs-Oct3/4 and 
pLKO.1-puro-scramble shRNA (3F-scramble), pMXs-Klf4, pMXs-Sox2, pMXs-Oct3/4 and 
pLKO.1-puro-TRF1 shRNA (3F-shTRF1). The procedure was repeated every 12 hours for 2 
days (a total of 4 additions). After infection was completed, media was replaced with 
standard ES media supplemented with knockout serum replacement (KSR, Invitrogen) and 
with puromycin to select for the shRNAs vectors. Cultures were maintained in the presence 
of drug selection with daily medium changes. Reprogramming was assessed 2 weeks post-
infection by counting alkaline phosphatase-positive colonies. Alkaline phosphatase staining 
was performed according to manufacturer´s instructions (BCIP/NBT Color Development 
Substrate, Promega). The results were normalized to the respective efficiencies of retroviral 
transduction as assessed by transducing with the three pMXsOct3/4, pMXsKlf4, pMXsSox2 
retroviruses plus a retrovirus expressing GFP. 
 
8.21.  GEN ER ATI ON  OF  M IC E  W I TH  C ON D IT I ON AL  TRF1  
AB L AT I ON  IN  TH E  SM AL L  IN TEST IN E  
Seven to nine-week old TRF1lox/lox; Villin-CreERT2+/T mice and control TRF1lox/lox; 
Villin-CreERT2+/T mice were injected intraperitonealy with 1mg 4-hydroxytamoxifen (Sigma) 
dissolved (by sonication) in 100µl corn oil (Sigma). Injections were performed on a daily base 
(for 34 days). Mouse weight was measured every day. Two TRF1lox/lox; Villin-CreERT2+/T 
mice had to be sacrificed before day 34 due to severe weight loss. Of all the mice the 
intestines were extracted washed out with PBS and prepared for western blot analysis, DNA-
extraction and paraffin embedding after fixation over night with formalin. Two small intestines 
were extracted on an early time point to check if excision is taking place from them, the 
TRF+/+ intestine was used in further experiments as control.  
 
8.22.  IHC  ST AI N IN GS  AN D  QU AN T IF IC AT I ON  
Immunohistochemistry was performed on deparaffinised sections processed with 10 
mM sodium citrate (pH 6.5) cooked under pressure for 2 min. Slides were washed in water, 
then in TBS-Tween20 0.5%, blocked with peroxidase, washed with TBS-Tween20 0.5 % 
again and blocked with fetal bovine serum followed by another washing step. Further, the 
slides were incubated with the primary antibodies: Villin at 1:2000 dillution (Dako; M3637) or 
caspase 3 activated at 1:200 (R&D SYSTEMS; AF835).Slides were then incubated with 
secondary antibodies conjugated with peroxidase (Dako). For signal development DAB 
(Dako) was used as a substrate. Sections were slightly counterstained with haematoxylin 
and analyzed by light microscopy. 
Apoptotic cells from H&E staining were histologically characterized by shrunk 
cytoplasm, condensed chromatin and the breakdown of the nucleus into fragments. 
Additionally we observed epithelial cells with irregular nucleus sizes (more than two times 
larger than normal) those cells were considered as endoreduplicated cells.  
In caspase 3 activated stained slides, cells that were positive for the peroxidise 
reaction where counted in a light microscope by eye.   
 
8.23.  TAI L  SK IN  P IGM ENT AT I O N  
 Tail skin hyperpigmentation was macroscopically analyzed according to (Stout & 
Blasco, 2009). 
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